COLLEGE OF MEDICINE AND HEALTH
Medicine, Nursing and Allied Health Professions

Profile

Loading content
Professor David Halpin

Professor David Halpin

Consultant Physician & Honorary Professor of Respiratory Medicine

 Smeall building 

 

Smeall Building, University of Exeter, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK

Overview

Professor Halpin was appointed as a Consultant Physician and Senior Lecturer in Respiratory Medicine in Exeter in 1994. He has a busy clinical practice and for 13 years he was Clinical Lead for the Department in Exeter, overseeing the growth in its clinical and research activity.  He is also Honorary Professor of Respiratory Medicine at the Observational and Pragmatic Research Institute (OPRI) in Singapore.  He is a member of the Board of Directors of the Global Initiative on Obstructive Lung Diseases (GOLD) and of the GOLD Science Committee.  He was the Chairman and Clinical Expert for the COPD Guideline Development Group of the National Institute of Clinical Excellence (NICE) in the UK.

He studied medicine at Brasenose College, Oxford University (first class honours) & St Thomas Hospital Medical School, qualifying in 1986.   He was awarded an MRC scholarship to undertake a D.Phil. in the Department of Human Anatomy at Oxford University, between his pre-clinical and clinical training.   He trained in respiratory medicine at the Royal Brompton Hospital in London.

He is a Fellow of Royal College Physicians, and a Member of the British Thoracic Society (BTS), European Respiratory Society (ERS) & American Thoracic Society (ATS).  He has served on various BTS committees.  In 2018 he was elected as a Fellow of ERS in recognition of lifetime excellence and contributions to research, education and clinical leadership in respiratory medicine.

Qualifications

  • BA Physiological Sciences, First Class, University of Oxford, 1981
  • DPhil, University of Oxford, 1983
  • MA, University of Oxford, 1983
  • MB BS, St Thomas's Hospital Medical School, London University 1986
  • MRCP, Royal College of Physicians London 1989
  • FRCP, Royal College of Physicians London, 1999
  • FERS, European Respiratory Society, 2018

Research

Research interests

His research is focused on clinical aspects of COPD and asthma.

He has led studies on the pharmacological treatment of asthma and COPD, including the effects of long acting-bronchodilators, inhaled corticosteroids and biologic therapies. He has recently led a real world pragmatic RCT examining the benefits of single versus multiple inhaler therapy in COPD.  Recent work has also looked at the role of biomarkers as predictors of therapeutic response.

He has also had a longstanding interests in the role of palliative care for patients with COPD and the role of psychological factors in COPD and asthma.

Research projects

  • MAGNIFY Trial: A pragmatic cluster randomized study evaluating a smart inhaler in patients with COPD
  • QUEST Study:  Predictors of response to Dupilumab in asthma.
  • CONQUEST: COPD quality improvement program development and cluster randomized RCT to assess efficacy in primary care
  • TRITON: Phase III study comparing efficacy, safety and tolerability of the fixed dose triple therapy with the fixed dose dual therapy in subjects with COPD

Publications

Key publications | Publications by category | Publications by year

Publications by category


Books

(2008). Chronic Kidney Disease National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care., Royal College of Physicians. Abstract.
(2006). Anaemia Management in Chronic Kidney Disease National Clinical Guideline for Management in Adults and Children., Royal College of Physicians.
Halpin DMG, Rudolf M, Yıldırım N, Demir T, Turgut Y (2006). Current COPD.
Halpin DMG (2003). Copd Your Questions Answered. Abstract.
Halpin DMG, Michael RMD (2002). Current COPD., Science Press Incorporated.
Halpin DMG (2001). COPD., Mosby Incorporated. Abstract.

Journal articles

Bafadhel M, Barnes N, Bourke SC, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MLK, Hartley B, Jones CE, et al (2021). A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. European Respiratory Journal, 58(3).
Bousquet J, Jutel M, Akdis CA, Klimek L, Pfaar O, Nadeau KC, Eiwegger T, Bedbrook A, Ansotegui IJ, Anto JM, et al (2021). ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy, 76(3), 689-697. Author URL.
Mammen MJ, Carr TF, Kraft M, Criner GJ, Dransfield MT, Wells JM, Halpin DMG, Han MK, Jain RG, Kaul V, et al (2021). All-cause mortality by subgroup in patients with chronic obstructive pulmonary disease: Post hoc analysis of the impact trial. Am. J. Respir. Crit. Care Med., 203(9). Abstract.  Author URL.
Wells JM, Bhatt SP, Dransfield MT, Carr TF, Kraft M, Criner GJ, Halpin DMG, Han MK, Jain R, Kaye MG, et al (2021). An analysis of the impact trial assessing single-inhaler therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI using a composite adverse event outcome in patients with copd. Am. J. Respir. Crit. Care Med., 203(9). Abstract.  Author URL.
Bourbeau J, Bafadhel M, Barnes NC, Compton C, Di Boscio V, Lipson DA, Jones PW, Martin N, Weiss G, Halpin DMG, et al (2021). Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 16, 499-517. Author URL.
Halpin DMG, Vogelmeier CF, Agusti AA (2021). COPD & COVID-19. ARCHIVOS DE BRONCONEUMOLOGIA, 57(3), 162-164. Author URL.
Bousquet J, Anto JM, Czarlewski W, Haahtela T, Fonseca SC, Iaccarino G, Blain H, Vidal A, Sheikh A, Akdis CA, et al (2021). Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. ALLERGY, 76(3), 735-750. Author URL.
Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MLK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, et al (2021). Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD: a Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. Chest, 159(3), 985-995. Abstract.
Halpin DMG, Vogelmeier CF, Mezzi K, Gupta P, Kostikas K, Wedzicha JA (2021). Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of ignite trials. ERJ Open Research, 7(1). Abstract.
Han MK, Agusti A, Celli BR, Criner GJ, Halpin DMG, Roche N, Papi A, Stockley RA, Wedzicha J, Vogelmeier CF, et al (2021). From GOLD 0 to Pre-COPD. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 203(4), 414-423. Author URL.
Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, Agusti AA, Vogelmeier CF (2021). Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. American Journal of Respiratory and Critical Care Medicine, 203(1), 24-36. Abstract.
Meghji J, Mortimer K, Agusti A, Allwood BW, Asher I, Bateman ED, Bissell K, Bolton CE, Bush A, Celli B, et al (2021). Improving lung health in low-income and middle-income countries: from challenges to solutions. LANCET, 397(10277), 928-940. Author URL.
Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Lange P, Lettis S, Lipson DA, Mannino D, Martin N, et al (2021). InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. RESPIRATORY RESEARCH, 22(1). Author URL.
Price D, Jones R, Pfister P, Cao H, Carter V, Kemppinen A, Holzhauer B, Kaplan A, Clark A, Halpin DMG, et al (2021). Maximizing Adherence and Gaining New Information for Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes. Pragmat Obs Res, 12, 25-35. Abstract.  Author URL.
Mahler DA, Halpin DMG (2021). Peak Inspiratory Flow as a Predictive Therapeutic Biomarker in COPD. CHEST, 160(2), 491-498. Author URL.
Han MK, Agusti A, Celli BR, Criner GJ, Halpin DMG, Roche N, Papi A, Stockley RA, Wedzicha J, Vogelmeier CF, et al (2021). Pre-Chronic Obstructive Pulmonary Disease: Toward the Limits of the Spirometric Funnel Reply. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 204(1), 112-112. Author URL.
Han MK, Criner GJ, Dransfield MT, Halpin DMG, Jones CE, Kilbride S, Lange P, Lettis S, Lipson DA, Lomas DA, et al (2021). Prognostic value of clinically important deterioration in copd: Impact trial analysis. ERJ Open Research, 7(1). Abstract.
Humbert M, Bourdin A, Papadopoulos NG, Holgate ST, Hanania NA, Halpin DMG, Chapman KR, Gavornikova M, Price DB, Kaplan A, et al (2021). Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. JOURNAL OF ASTHMA, 58(7), 849-854. Author URL.
Mapel DW, Bogart M, Jain R, Criner GJ, Dransfield MT, Gaeckle N, Gotfried M, Halpin DMG, Han MK, Kaul V, et al (2021). Reduction in emergency department (ED) visits in patients with chronic obstructive pulmonary disease (Copd): Analysis of the impact trial. Am. J. Respir. Crit. Care Med., 203(9). Abstract.  Author URL.
Jones R, Davis A, Stanley B, Julious S, Ryan D, Jackson DJ, Halpin DMG, Hickman K, Pinnock H, Quint JK, et al (2021). Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. Pragmat Obs Res, 12, 93-104. Abstract.  Author URL.
Mammen MJ, Carr TF, Kraft M, Criner GJ, Dransfield MT, Wells JM, Halpin DMG, Han MK, Hartley B, Jain R, et al (2021). Risk of all-cause mortality during and after severe exacerbations in patients with chronic obstructive pulmonary disease (Copd): Post hoc analysis of the impact trial. Am. J. Respir. Crit. Care Med., 203(9). Abstract.  Author URL.
Dransfield MT, Crim C, Criner GJ, Day NC, Halpin DMG, Han MLK, Elaine Jones C, Kilbride S, LaFon D, Lipson DA, et al (2021). Risk of exacerbation and pneumonia with single-inhaler triple versus dual therapy in IMPACT. Annals of the American Thoracic Society, 18(5), 788-798. Abstract.
Corbetta L, Fabbri LM, Halpin D, Cruz AA, Zanconato S (2021). Stand on the Same Side Against Covid – 19: Ics-Containing Products in Treatment Covid-19 Patients with Asthma and COPD. Substantia, 1234-1234. Abstract.
Halpin DMG, Criner GJ, Dransfield MT, Han MLK, Hartley B, Harvey C, Jones CE, Kato M, Lange P, Lettis S, et al (2021). Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. Pulmonary Therapy, 7(1), 101-118. Abstract.
Ming SWY, Haughney J, Ryan D, Small I, Lavorini F, Papi A, Singh D, Halpin DMG, Hurst JR, Patel S, et al (2020). A comparison of the real-life clinical effectiveness of the leading licensed ics/laba combination inhalers in the treatment for copd. International Journal of COPD, 15, 3093-3103. Abstract.
To T, Viegi G, Cruz A, Taborda-Barata L, Asher I, Behera D, Bennoor K, Boulet L-P, Bousquet J, Camargos P, et al (2020). A global respiratory perspective on the COVID-19 pandemic: commentary and action proposals. Eur Respir J, 56(1). Author URL.
Kerkhof M, Chaudhry I, Pavord ID, Miravitlles M, Kook Rhee C, Halpin DMG, Usmani OS, Jones R, Kocks J, Alacqua M, et al (2020). Blood eosinophil count predicts treatment failure and hospital readmission for COPD. ERJ Open Res, 6(4). Abstract.  Author URL.
(2020). COVID-19 pandemic alert: time to focus on lung health-Beijing call to action for lung health promotion. Journal of Thoracic Disease, 12(6), 3238-3241.
Rabe KF, Halpin DMG, Han MK, Miravitlles M, Singh D, Groenke L, Voss F, Martinez FJ (2020). Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. RESPIRATORY RESEARCH, 21(1). Author URL.
Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A (2020). Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?. The Lancet Respiratory Medicine, 8(5), 436-438.
Kaplan A, Szefler SJ, Halpin DMG (2020). Impact of comorbid conditions on asthmatic adults and children. npj Primary Care Respiratory Medicine, 30(1). Abstract.
Singh D, Halpin DMG (2020). Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying?. The Lancet Respiratory Medicine, 8(11), 1065-1066.
Halpin DMG, Singh D, Hadfield RM (2020). Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. EUROPEAN RESPIRATORY JOURNAL, 55(5). Author URL.
Halpin DM, Worsley S, Ismaila AS, Astrom J, Beeh KM, Brintziki D, Tabberer M, Di Boscio V, Compton C, Kocks J, et al (2020). Intrepid: Clinical effectiveness of once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol versus multiple-inhaler triple therapy in usual clinical practice. Am. J. Respir. Crit. Care Med., 201(1). Abstract.  Author URL.
Bousquet J, Cristol JP, Czarlewski W, Anto JM, Martineau A, Haahtela T, Fonseca SC, Iaccarino G, Blain H, Fiocchi A, et al (2020). Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. Clinical and Translational Allergy, 10(1). Abstract.
Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, et al (2020). Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 201(12), 1508-1516. Abstract.  Author URL.
Tabberer M, Jones CE, Kilbride S, Halpin DMG, Lomas DA, Pascoe S, Singh D, Wise RA, Criner GJ, Lange P, et al (2020). Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: the IMPACT Study. Advances in Therapy, 37(9), 3775-3790. Abstract.
Day NC, Kumar S, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kaisermann MC, Kilbride S, Lange P, et al (2020). Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: Results on cardiovascular safety from the IMPACT trial. Respiratory Research, 21(1). Abstract.
Halpin DMG, Dransfield MT, Han MLK, Elaine Jones C, Kilbride S, Lange P, Lipson DA, Lomas DA, Martinez FJ, Pascoe S, et al (2020). The effect of exacerbation history on outcomes in the impact trial. European Respiratory Journal, 55(6). Abstract.
Han MLK, Criner GJ, Dransfield MT, Halpin DMG, Elaine Jones C, Kilbride S, Lange P, Lettis S, Lipson DA, Lomas DA, et al (2020). The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study a randomized, double-blind, multicenter clinical trial. American Journal of Respiratory and Critical Care Medicine, 202(9), 1237-1243. Abstract.
FitzGerald JM, Buhl R, Casale TB, Jugovic B, Zaremba-Pechmann L, Halpin DMG (2020). Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma. EUROPEAN RESPIRATORY JOURNAL, 55(1). Author URL.
Halpin DMG (2020). What is Asthma Chronic Obstructive Pulmonary Disease Overlap?. Clinics in Chest Medicine, 41(3), 395-403. Abstract.
Price DB, Bosnic-Anticevich S, Pavord ID, Roche N, Halpin DMG, Bjermer L, Usmani OS, Brusselle G, Ming SWY, Rastogi S, et al (2019). Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. Clinical and Translational Allergy, 9(1). Abstract.
Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MLK, Hartley B, Lange P, et al (2019). Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. The Lancet Respiratory Medicine, 7(9), 745-756. Abstract.
Pascoe S, Barnes N, Compton C, Hilton E, Van Der Valk RJP, Brusselle G, Criner G, Dransfield M, Halpin DMG, Han MK, et al (2019). Bzlood eosinophil counts and treatment response in COPD: Analyses of IMPACT. Pneumologie, 73(SUPPPL. 1). Abstract.
Stockley RA, Halpin DMG, Celli BR, Singh D (2019). Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 199(10), 1195-1204. Author URL.
Halpin D (2019). Chronic Obstructive Pulmonary Disease and Work: is it Time to Stop?. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 200(10), 1195-1197. Author URL.
Worsley S, Snowise N, Halpin DMG, Midwinter D, Ismaila AS, Irving E, Sansbury L, Tabberer M, Leather D, Compton C, et al (2019). Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/ vilanterol in usual practice: the COPD INTREPID study design. ERJ Open Research, 5(4). Abstract.
Lipson DA, Barnhart F, Crim C, Jones CE, Boucot I, Brealey N, Kilbride S, Criner G, Dransfield M, Halpin DMG, et al (2019). Comparison of LAMA/LABA vs. ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie, 73(SUPPPL. 1). Abstract.
Stockley RA, Halpin D, Celli BR, Singh D (2019). Confounding Factors Affecting sRAGE as a Biomarker for Chronic Obstructive Pulmonary Disease Reply. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 200(1), 114-115. Author URL.
Ismaila AS, Risebrough N, Schroeder M, Shah D, Martin A, Goodall EC, Ndirangu K, Criner G, Dransfield M, Halpin DMG, et al (2019). Cost-Effectiveness of Once-Daily Single-Inhaler Triple Therapy in COPD: the IMPACT Trial. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 14, 2681-2695. Author URL.
Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, et al (2019). Current Controversies in Chronic Obstructive Pulmonary Disease a Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. ANNALS OF THE AMERICAN THORACIC SOCIETY, 16(1), 29-39. Author URL.
Halpin DMG, de Jong HJI, Carter V, Skinner D, Price D (2019). Distribution, Temporal Stability and Appropriateness of Therapy of Patients with COPD in the UK in Relation to GOLD 2019. EClinicalMedicine, 14, 32-41. Abstract.
Lipson DA, Barnhart F, Boucot I, Naya I, Crim C, Jones CE, Brealey N, Kilbride S, Criner G, Dransfield M, et al (2019). Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. Pneumologie, 73(SUPPPL. 1). Abstract.
Singh SJ, Halpin DMG, Salvi S, Kirenga BJ, Mortimer K (2019). Exercise and pulmonary rehabilitation for people with chronic lung disease in LMICs: challenges and opportunities. LANCET RESPIRATORY MEDICINE, 7(12), 1002-1004. Author URL.
Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, et al (2019). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. EUROPEAN RESPIRATORY JOURNAL, 53(5). Author URL.
Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, et al (2019). InforMing the pathway of COPD treatment (The IMPACT study): Single inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol) versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: an analysis based on baseline COPD medication use. Am. J. Respir. Crit. Care Med., 199(9). Abstract.  Author URL.
Halpin DMG, Celli BR, Criner GJ, Frith P, Victorina López Varela M, Salvi S, Vogelmeier CF, Chen R, Mortimer K, Montes de Oca M, et al (2019). It is time for the world to take COPD seriously: a statement from the GOLD board of directors. European Respiratory Journal, 54(1).
Hartley B, Criner GJ, Dransfield MT, Halpin DMG, Han MLK, Elaine Jones C, Kilbride S, Lange P, Lipson DA, Lomas DA, et al (2019). Misinterpretation of time-to-first event curves can lead to inappropriate treatment. European Respiratory Journal, 54(3).
Hartley B, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, et al (2019). Misinterpretation of time-to-first event curves can lead to inappropriate treatment. EUROPEAN RESPIRATORY JOURNAL, 54(3). Author URL.
Halpin DMG, Meltzer EO, Pisternick-Ruf W, Moroni-Zentgraf P, Engel M, Zaremba-Pechmann L, Casale T, FitzGerald JM (2019). Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV1. RESPIRATORY RESEARCH, 20 Author URL.
Lipson DA, Criner GJ, Day N, Kilbride S, Midwinter D, Dransfield MT, Halpin DM, Han MK, Jones C, Manchester P, et al (2019). Reduction in the risk of all-cause mortality with fluticasone furoate/umeclidinium/vilanterol compared to umeclidinium/vilanterol in IMPACT including previously missing or censored vital status data. Am. J. Respir. Crit. Care Med., 199(9). Abstract.  Author URL.
Dransfield M, Crim C, Jones CE, Criner G, Halpin DMG, Han MK, Kilbride S, Lange P, Lipson DA, Lomas DA, et al (2019). Risk of Exacerbation and Pneumonia with Single Inhaler Triple versus Dual Therapie in IMPACT. Pneumologie, 73(SUPPPL. 1). Abstract.
Halpin DMG, Celli BR, Criner GJ, Frith P, López Varela MV, Salvi S, Vogelmeier CF, Chen R, Mortimer K, Montes de Oca M, et al (2019). The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries. International Journal of Tuberculosis and Lung Disease, 23(11), 1131-1141. Abstract.
Miravitlles M, Roche N, Cardoso J, Halpin D, Aisanov Z, Kankaanranta H, Kobližek V, Śliwiński P, Bjermer L, Tamm M, et al (2018). Chronic obstructive pulmonary disease guidelines in Europe: a look into the future. Respir Res, 19(1). Abstract.  Author URL.
Halpin DMG, FitzGerald JM, Engel M, Moroni-Zentgraf P, Sigmund R, Meltzer EO, Casale TB (2018). Comparison of PEF vs. FEV1 endpoints in trials with tiotropium in adults and adolescents with moderate or severe symptomatic asthma. J. Allergy Clin. Immunol., 141(2 Supplement 1). Abstract.
Tashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A (2018). Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT (R) trial. RESPIRATORY RESEARCH, 19 Author URL.
Moroni-Zentgraf P, Usmani OS, Halpin DMG (2018). Inhalation Devices. CANADIAN RESPIRATORY JOURNAL, 2018 Author URL.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, et al (2018). Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med, 378(18), 1671-1680. Abstract.  Author URL.
Halpin DMG (2018). Palliative Care for Chronic Obstructive Pulmonary Disease Signs of Progress, but Still a Long Way to Go. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 198(11), 1356-1358. Author URL.
Halpin DMG (2018). Palliative care for people with COPD: effective but underused. EUROPEAN RESPIRATORY JOURNAL, 51(2). Author URL.
Rabe KF, Halpin D, Martinez F, Singh D, Han MK, Zehendner CM, Gronke L, Voss F, Miravittlles M (2018). Relative timing of clinically important deterioration and related long-term outcomes in COPD: a post hoc analysis of the UPLIFT study. Pneumologie, 72(Supplement 1). Abstract.
Halpin DMG, Birk R, Brealey N, Criner GJ, Dransfield MT, Hilton E, Lomas DA, Zhu CQ, Lipson DA (2018). Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses. ERJ Open Research, 4(2). Abstract.
Halpin DMG (2018). The role of tiotropium+olodaterol dual bronchodilator therapy in the management of chronic obstructive pulmonary disease. Tuberculosis and Respiratory Diseases, 81(1), 13-18. Abstract.
FitzGerald JM, Buhl R, Casale TB, El Azzi G, Engel M, Sigmund R, Halpin DM (2018). Tiotropium respimat reduces episodes of asthma worsening in primotina-asthma Irrespective of Baseline Characteristics or Season. Am. J. Respir. Crit. Care Med., 197(MeetingAbstracts). Abstract.  Author URL.
Halpin DMG (2018). Understanding irrationality: the key to changing behaviours and improving management of respiratory diseases?. LANCET RESPIRATORY MEDICINE, 6(10), 737-739. Author URL.
Williamson GR, O'Connor A, Chamberlain C, Halpin D (2018). mHealth resources for asthma and pregnancy care: Methodological issues and social media recruitment. A discussion paper. J Adv Nurs, 74(10), 2442-2449. Abstract.  Author URL.
Halpin DMG, Decramer M, Celli BR, Mueller A, Metzdorf N, Tashkin DP (2017). Effect of a single exacerbation on decline in lung function in COPD. Respiratory Medicine, 128, 85-91. Abstract.
Halpin D (2017). GOLD 2017 report brings new recommendations on assessing chronic obstructive pulmonary disease. BRITISH JOURNAL OF HOSPITAL MEDICINE, 78(3), 129-129. Author URL.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Respirology, 22(3), 575-601. Abstract.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 195(5), 557-582. Author URL.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. EUROPEAN RESPIRATORY JOURNAL, 49(3). Author URL.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. ARCHIVOS DE BRONCONEUMOLOGIA, 53(3), 128-149. Author URL.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary (vol 49, 1700214, 2017). EUROPEAN RESPIRATORY JOURNAL, 49(6). Author URL.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary (vol 53, pg 128, 2017). ARCHIVOS DE BRONCONEUMOLOGIA, 53(7), 411-412. Author URL.
Halpin DMG, Miravitlles M, Metzdorf N, Celli B (2017). Impact and prevention of severe exacerbations of COPD: a review of the evidence. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 12, 2891-2908. Author URL.
Thomas M, Halpin DMG, Miravitlles M (2017). When is dual bronchodilation indicated in COPD?. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 12, 2291-2305. Author URL.
Halpin DM, Kaplan AG, Russell RK (2017). Why choose tiotropium for my patient? a comprehensive review of actions and outcomes versus other bronchodilators. RESPIRATORY MEDICINE, 128, 28-41. Author URL.
Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, Kankaanranta H, Sandström T, Śliwiński P, Zatloukal J, et al (2016). A review of national guidelines for management of COPD in Europe. Eur Respir J, 47(2), 625-637. Abstract.  Author URL.
Halpin D, Holmes S, Calvert J, McInerney D (2016). Case finding for chronic obstructive pulmonary disease in people attending long-term condition clinics in primary care. Chron Respir Dis, 13(4), 337-343. Abstract.  Author URL.
Singh D, Roche N, Halpin D, Agusti A, Wedzicha JA, Martinez FJ (2016). Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 194(5), 541-549. Abstract.  Author URL.
Lange P, Halpin DM, O'Donnell DE, MacNee W (2016). Diagnosis, assessment, and phenotyping of COPD: beyond FEV₁. International journal of chronic obstructive pulmonary disease, 11 Spec, 3-12. Abstract.
Halpin DMG, Vogelmeier C, Pieper MP, Metzdorf N, Richard F, Anzueto A (2016). Effect of tiotropium on COPD exacerbations: a systematic review. RESPIRATORY MEDICINE, 114, 1-8. Author URL.
Halpin DMG, Kerkhof M, Soriano JB, Mikkelsen H, Price DB (2016). Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. RESPIRATORY RESEARCH, 17 Author URL.
Hyland ME, Halpin DMG, Blake S, Seamark C, Pinnuck M, Ward D, Whalley B, Greaves CJ, Hawkins AL, Seamark D, et al (2016). Preference for different relaxation techniques by COPD patients: Comparison between six techniques. International Journal of COPD, 11(1), 2315-2319. Abstract.  Full text.
Dahl R, Engel M, Dusser D, Halpin D, Kerstjens HAM, Zaremba-Pechmann L, Moroni-Zentgraf P, Busse WW, Bateman ED (2016). Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: a pooled safety analysis. Respir Med, 118, 102-111. Abstract.  Author URL.
Paggiaro P, Halpin DMG, Buhl R, Engel M, Zubek VB, Blahova Z, Moroni-Zentgraf P, Pizzichini E (2016). The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: a Randomized Controlled Trial. Journal of Allergy and Clinical Immunology: in Practice, 4(1), 104-113.e2. Abstract.
Halpin DMG (2016). Tiotropium in asthma: What is the evidence and how does it fit in?. World Allergy Organization Journal, 9(1). Abstract.
Halpin D, Banks L, Martello A (2016). Working together to go ‘beyond the pill’: Building a virtuous network of collaborators. BMJ Innovations, 2(1), 1-3.
Saleh A, López-Campos JL, Hartl S, Pozo-Rodríguez F, Roberts CM (2015). The Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data from the European COPD Audit. PLOS ONE, 10(7), e0134004-e0134004.
Halpin DMG, Dahl R, Hallmann C, Mueller A, Tashkin D (2015). Tiotropium HandiHaler (R) and Respimat (R) in COPD: a pooled safety analysis. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 10, 239-259. Author URL.
Calverley P, Hallmann C, Metzdorf N, Grnke L, Mueller A, Halpin D (2015). Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels. Eur. Respir. J., 46(SUPPL. 59). Abstract.  Author URL.
Halpin D, Hyland M, Blake S, Seamark C, Pinnuck M, Ward D, Whalley B, Greaves C, Hawkins A, Seamark D, et al (2015). Understanding fear and anxiety in patients at the time of an exacerbation of chronic obstructive pulmonary disease: a qualitative study. JRSM Open, 6(12). Abstract.  Author URL.
Sarran C, Halpin D, Levy ML, Prigmore S, Sachon P (2014). A retrospective study of the impact of a telephone alert service (Healthy Outlook) on hospital admissions for patients with chronic obstructive pulmonary disease. NPJ Prim Care Respir Med, 24 Abstract.  Author URL.
Tashkin DP, Li N, Kleerup EC, Halpin D, Celli B, Decramer M, Elashoff R (2014). Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. Respir Res, 15 Abstract.  Author URL.
Jones RCM, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, Burden A, Halpin DMG, Winter R, Hill S, et al (2014). Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. The Lancet Respiratory Medicine, 2(4), 267-276. Abstract.
Jones RCM, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, Burden A, Halpin DMG, Winter R, Hill S, et al (2014). Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. The Lancet Respiratory Medicine
Halpin DMG, Quint JK (2014). The WISDOM of inhaled corticosteroids in COPD. THORAX, 69(12), 1071-1072. Author URL.
Tashkin DP, Li N, Halpin D, Kleerup E, Decramer M, Celli B, Elashoff R (2013). Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. Respir Med, 107(12), 1904-1911. Abstract.  Author URL.
Verceles AC, Lechner EJ, Halpin D, Scharf SM (2013). The association between comorbid illness, colonization status, and acute hospitalization in patients receiving prolonged mechanical ventilation. Respir Care, 58(2), 250-256. Abstract.  Author URL.
Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, et al (2013). Tiotropium Respimat Inhaler and the Risk of Death in COPD. New England Journal of Medicine, 369(16), 1491-1501.
Small N, Gardiner C, Barnes S, Gott M, Halpin D, Payne S, Seamark D (2012). "You get old, you get breathless, and you die": chronic obstructive pulmonary disease in Barnsley, UK. Health Place, 18(6), 1396-1403. Abstract.  Author URL.
Tashkin DP, Wang HJ, Halpin D, Kleerup EC, Connett J, Li N, Elashoff R (2012). Comparison of the variability of the annual rates of change in FEV <inf>1</inf> determined from serial measurements of the pre- versus post-bronchodilator FEV <inf>1</inf> over 5 years in mild to moderate COPD: Results of the lung health study. Respiratory Research, 13 Abstract.
Barnes S, Gardiner C, Gott M, Payne S, Chady B, Small N, Seamark D, Halpin D (2012). Enhancing patient-professional communication about end-of-life issues in life-limiting conditions: a critical review of the literature. J Pain Symptom Manage, 44(6), 866-879. Abstract.  Author URL.
Halpin DMG, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP (2012). Exacerbation frequency and course of COPD. International Journal of COPD, 7, 653-661. Abstract.
Hyland ME, Whalley B, Halpin DMG, Greaves CJ, Seamark C, Blake S, Pinnuck M, Ward D, Hawkins A, Seamark D, et al (2012). Frequency of non-asthma GP visits predicts asthma exacerbations: an observational study in general practice. Primary Care Respiratory Journal
Hyland ME, Whalley B, Halpin DMG, Greaves CJ, Seamark C, Blake S, Pinnuck M, Ward D, Hawkins AL, Seamark D, et al (2012). Frequency of non-asthma GP visits predicts asthma exacerbations: an observational study in general practice. Primary Care Respiratory Journal, 21(4), 405-411. Abstract.
Seamark D, Blake S, Seamark S, Hyland M, Greaves CJ, Pinnuck M, Ward D, Hawkins A, Halpin D (2012). Is hospitalization for COPD an opportunity for Advance Care Planning? a qualitative study. Primary Care Respiratory Journal, 21(3), 261-266. Abstract.
Halpin DMG, Laing-Morton T, Spedding S, Levy ML, Coyle P, Lewis J, Newbold P, Marno P (2011). A randomised controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. Primary Care Respiratory Journal, 20(3), 324-331. Abstract.
Halpin DMG, Laing-Morton T, Spedding S, Levy ML, Coyle P, Lewis J, Newbold P, Marno P (2011). A randomised controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. Primary Care Respiratory Journal
Halpin DMG, Gray J, Edwards SJ, Morais J, Singh D (2011). Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 65(7), 764-774. Author URL.
Halpin DMG (2011). Improving the management of COPD. BMJ, 342(7801).
Halpin DMG, Decramer M, Celli B, Kesten S, Leimer I, Tashkin DP (2011). Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFT (R) Trial. LUNG, 189(4), 261-268. Author URL.
Marno P, Chalder M, Laing-Morton T, Levy M, Sachon P, Halpin D (2010). Can a health forecasting service offer COPD patients a novel way to manage their condition?. Journal of Health Services Research and Policy, 15(3), 150-155. Abstract.
Gardiner C, Gott M, Payne S, Small N, Barnes S, Halpin D, Ruse C, Seamark D (2010). Exploring the care needs of patients with advanced COPD: an overview of the literature. Respir Med, 104(2), 159-165. Abstract.  Author URL.
Halpin DMG (2010). Lessons from the major studies in COPD: Problems and pitfalls in translating research evidence into practice. Primary Care Respiratory Journal, 19(2), 170-179. Abstract.
Gardiner C, Barnes S, Small N, Gott M, Payne S, Seamark D, Halpin D (2010). Reconciling informed consent and 'do no harm': ethical challenges in palliative-care research and practice in chronic obstructive pulmonary disease. Palliat Med, 24(5), 469-472. Abstract.  Author URL.
Gott M, Gardiner C, Small N, Payne S, Seamark D, Halpin D, Ruse C, Barnes S (2010). The effect of the Shipman murders on clinician attitudes to prescribing opiates for dyspnoea in end-stage chronic obstructive pulmonary disease in England. Progress in Palliative Care, 18(2), 79-84. Abstract.
Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M (2010). Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT(R) trial. European Respiratory Journal, 36(1), 65-73.
Small N, Gardiner C, Barnes S, Gott M, Payne S, Seamark D, Halpin D (2010). Using a prediction of death in the next 12 months as a prompt for referral to palliative care acts to the detriment of patients with heart failure and chronic obstructive pulmonary disease. Palliat Med, 24(7), 740-741. Author URL.
Gott M, Gardiner C, Small N, Payne S, Seamark D, Barnes S, Halpin D, Ruse C (2009). Barriers to advance care planning in chronic obstructive pulmonary disease. Palliat Med, 23(7), 642-648. Abstract.  Author URL.
Halpin DMG, Tashkin DP (2009). Defining disease modification in chronic obstructive pulmonary disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 6(3), 211-225. Abstract.
Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP (2009). Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. The Lancet, 374(9696), 1171-1178.
Hyland ME, Blake S, Greaves CJ, Pinnuck M, Seamark C, Seamark D, Ward D, Halpin DMG (2009). Guidelines versus practice: UK asthma nurses often recommend intermittent, symptom-driven use of inhaled corticosteroids. Prim Care Respir J, 18(2), 114-117. Abstract.  Author URL.
Gardiner C, Gott M, Small N, Payne S, Seamark D, Barnes S, Halpin D, Ruse C (2009). Living with advanced chronic obstructive pulmonary disease: patients concerns regarding death and dying. Palliat Med, 23(8), 691-697. Abstract.  Author URL.
Halpin D, Menjoge S, Viel K (2009). Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations. Prim Care Respir J, 18(2), 106-113. Abstract.  Author URL.
Halpin DMG (2009). Preventing chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 3(5), 449-452.
Bryden C, Bird W, Titley HA, Halpin DMG, Levy ML (2009). Stratification of COPD patients by previous admission for targeting of preventative care. RESPIRATORY MEDICINE, 103(4), 558-565. Author URL.
Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M (2008). A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 359(15), 1543-1554.
Halpin DMG (2008). ABCD of the phosphodiesterase family: Interaction and differential activity in COPD. International Journal of COPD, 3(4), 543-561. Abstract.
Price L, Kassianos G, Brown MJ, Gaw A, Kirby M, Morrell J, Schachter M, Tamargo J, Yawn B, Yawn R, et al (2008). Aliskiren - the first of a new class of antihypertensive. Drugs in Context, 4(1), 105-120. Abstract.
Chambers S, Kassianos G, Brown P, Gaw A, Kirby M, Morrell J, Schachter M, Tamargo J, Yawn B, Yawn R, et al (2008). Cervarix - Preventing cervical cancer and other diseases related to HPV. Drugs in Context, 4(1), 59-70. Abstract.
Halpin DMG (2008). Community care for COPD: the good, the bad and the ugly. THORAX, 63(3), 187-189. Author URL.
Croom K, Kassianos G, Schachter M, Morrell J, Gaw A, Kirby M, Tamargo J, Yawn B, Yawn R, Barakat K, et al (2008). Coversyl Plus - Treating hypertension and improving clinical outcomes in T2D and other high risk groups. Drugs in Context, 4(1), 71-84. Abstract.
Halpin DMG, Seamark CJ, Seamark DA (2008). End-of-life care for patients with COPD in the community setting. BRITISH JOURNAL OF GENERAL PRACTICE, 58(551), 390-392. Author URL.
Croom K, Kassianos G, Gaw A, Kirby M, Morrell J, Schachler M, Tamargo J, Yawn B, Yawn R, Barakal K, et al (2008). Ezetimibe - a clinically effective and a cost-effective treatment option for dyslipidaemia. Drugs in Context, 4(1), 85-104. Abstract.
Chambers S, Kassianos G, Brown P, Gaw A, Kirby M, Morrell J, Schachter M, Tamargo J, Yawn B, Yawn R, et al (2008). Gardasil - Preventing cervical cancer and other diseases related to HPV. Drugs in Context, 4(1), 29-40. Abstract.
Crowe E, Halpin D, Stevens P, Grp GD (2008). Guidelines - Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ-BRITISH MEDICAL JOURNAL, 337(7673). Author URL.
Halpin DMG, Peterson S, Larsson TP, Calverley PMA (2008). Identifying COPD patients at increased risk of mortality: Predictive value of clinical study baseline data. Respiratory Medicine, 102(11), 1615-1624. Abstract.
Croom K, Kassianos G, Schachter M, Morrell J, Gaw A, Kirby M, Tamargo J, Yawn B, Yawn R, Barakat K, et al (2008). Inegy - Effective combination treatment to target LDL-C levels. Drugs in Context, 4(1), 41-58. Abstract.
Halpin D (2008). Mortality in COPD: Inevitable or Preventable? Insights from the Cardiovascular Arena. COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 5(3), 187-200. Author URL.
Halpin DMG (2008). Symbicort: a pharmacoeconomic review. Journal of Medical Economics, 11(2), 345-362. Abstract.
Chambers S, Schachter M, Morrell J, Kassianos G, Gaw A, Kirby M, Tamargo J, Yawn B, Yawn R, Barakat K, et al (2008). Telmisartan - an effective antihypertensive for 24-hour blood pressure control. Drugs in Context, 4(1), 1-14. Abstract.
Chambers S, Schachter M, Price D, Kassianos G, Gaw A, Kirby M, Morrell J, Tamargo J, Yawn B, Yawn R, et al (2008). Tiotropium - Advancing the treatment of COPD. Drugs in Context, 4(1), 15-28. Abstract.
Halpin DMG (2008). Uplifting times for COPD. Primary Care Respiratory Journal, 17(4), 197-198.
Halpin DMG, O'Reilly JF, Connellan S, Rudolf M (2007). Confidence and understanding among general practitioners and practice nurses in the UK about diagnosis and management of COPD. RESPIRATORY MEDICINE, 101(11), 2378-2385. Author URL.
Halpin DMG (2007). Management of exacerbations of chronic obstructive pulmonary disease. Minerva Pneumologica, 46(1), 5-17. Abstract.
Seamark DA, Seamark CJ, Halpin DMG (2007). Palliative care in chronic obstructive pulmonary disease: a review for clinicians. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 100(5), 225-233. Author URL.
Halpin DM (2007). Systemic effects of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 1(1), 75-84. Abstract.
Halpin DMG (2006). Assessing the severity of COPD. Primary Care Respiratory Journal, 15(2), 78-80.
Halpin DMG (2006). Chronic obstructive pulmonary disease, inflammation and PDE4 inhibitors. BRITISH JOURNAL OF HOSPITAL MEDICINE, 67(7), 370-374. Author URL.
Halpin DMG (2006). Diagnosing COPD. International journal of chronic obstructive pulmonary disease, 1(4), 343-344.
Halpin D (2006). Editorial. Drugs in Context, 2(6), 231-232.
Dyer MJ, Halpin DMG, Stein K (2006). Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review. BMC Fam Pract, 7 Abstract.  Author URL.
Halpin DMG (2006). The diagnosis and management of COPD in older people. CME Journal Geriatric Medicine, 8(1), 11-17. Abstract.
(2005). Beta2 agonist reversibility testing in COPD diagnosis. Drug and Therapeutics Bulletin, 43(12), 89-91.
Halpin DMG (2005). Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis. International Journal of Clinical Practice, 59(10), 1187-1194. Abstract.
Halpin DMG (2005). NICE versus nGMS: What the evidence tells us. Primary Care Respiratory Journal, 14(1), 8-10.
Greaves CJ, Hyland ME, Halpin DMG, Blake S, Seamark D (2005). Patterns of corticosteroid medication use: non-adherence can be effective in milder asthma. Prim Care Respir J, 14(2), 99-105. Abstract.  Author URL.
Pearson M (2004). Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax, 59(SUPPL. 1), 1-232.
Ward DG, Halpin DMG, Seamark DA (2004). How accurate is a diagnosis of asthma in a general practice database? a review of patients' notes and questionnaire-reported symptoms. British Journal of General Practice, 54(507), 753-758. Abstract.
Seamark DA, Blake SD, Seamark CJ, Halpin DMG (2004). Living with severe chronic obstructive pulmonary disease (COPD): Perceptions of patients and their carers. An interpretative phenomenological analysis. Palliative Medicine, 18(7), 619-625. Abstract.
Halpin D (2004). NICE guidance for COPD. Thorax, 59(3), 181-182. Author URL.
Celli B, Halpin D, Hepburn R, Byrne N, Keating ET, Goldman M (2003). Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS). Respir Med, 97 Suppl A, S35-S43. Abstract.  Author URL.
Greaves CJ, Eiser C, Seamark D, Halpin DMG (2002). Attack context: an important mediator of the relationship between psychological status and asthma outcomes. Thorax, 57(3), 217-221. Abstract.  Author URL.
Ward JA, Akers G, Ward DG, Pinnuck M, Williams S, Trott J, Halpin DMG (2002). Feasibility and effectiveness of a pulmonary rehabilitation programme in a community hospital setting. British Journal of General Practice, 52(480), 539-542. Abstract.
Sweeney KG, Edwards K, Stead J, Halpin D (2001). A comparison of professionals' and patients' understanding of asthma: Evidence of emerging dualities?. Medical Humanities, 27(1), 20-25. Abstract.
Seamark DA, Williams S, Timon S, Ward A, Ward D, Seamark C, Pinnuck M, Powell R, Halpin D (2001). Home or surgery based screening for chronic obstructive pulmonary disease (COPD)?. Primary Care Respiratory Journal, 10(2), 30-33. Abstract.
Halpin D (2001). Managing pneumonia in general practice. Practitioner, 245(1619), 108-115. Author URL.
(2001). Managing stable chronic obstructive pulmonary disease. Drug and Therapeutics Bulletin, 39(11), 81-85.
Furness J, Fearby S, Clough JB, Clark CE, Coote JM, Silver DAT, Halpin DMG (2000). Asthma after childhood pneumonia. BMJ, 321(7271).
Clark CE, Coote JM, Silver DAT, Halpin DMG (2000). Asthma after childhood pneumonia - Reply. BRITISH MEDICAL JOURNAL, 321(7271), 1290-1290. Author URL.
Furness J, Fearby S, Clough JB, Clark CE, Coote JM, Silver DAT, Halpin DMG (2000). Asthma after childhood pneumonia [7] (multiple letters). British Medical Journal, 321(7271), 1289-1290.
Clark CE, Coote JM, Silver DAT, Halpin DMG (2000). Asthma after childhood pneumonia: six year follow up study. BRITISH MEDICAL JOURNAL, 320(7248), 1514-1516. Author URL.
Connolly KC, Peake MD, Halpin DMG, Golightly L, Turbitt ML (2000). Challenging current asthma treatment guidelines: Improved control of asthma symptoms with nebulised budesonide in patients with severe asthma receiving continuous oral steroids. Disease Management and Health Outcomes, 7(4), 217-225. Abstract.
Halpin DMG, Hart E, Harris T, Harbour R, Rudolf M (2000). What do general practice records tell us about the current management of COPD and the impact of the BTS COPD guidelines?. Thorax, 55(SUPPL. 3). Abstract.
Halpin DMG, Williams S, Timon S, Ward AW, Ward DW, Seamark CJ, Pinnuck M, Seamark DA (1999). Home or surgery based screening for COPD?. Thorax, 54(SUPPL. 3). Abstract.
Forsling ML, Montgomery H, Halpin D, Windle RJ, Treacher DF (1998). Daily patterns of secretion of neurohypophysial hormones in man: effect of age. Exp Physiol, 83(3), 409-418. Abstract.  Author URL.
Bramwell EC, Halpin DMG, Duncan‐Skingle F, Hodson ME, Geddes DM (1995). Home treatment of patients with cystic fibrosis using the‘Intermate’: the first year's experience. Journal of Advanced Nursing, 22(6), 1063-1067. Abstract.
Halpin DMG, Graneek BJ, Turner-Warwick M, Taylor AJN (1994). Extrinsic allergic alveolitis and asthma in a sawmill worker: Case report and review of the literature. Occupational and Environmental Medicine, 51(3), 160-164. Abstract.
Halpin DMG, Graneek BJ, Lacey J, Nieuwenhuijsen MJ, Williamson PAM, Venables KM, Taylor AJN (1994). Respiratory symptoms, immunological responses, and aeroallergen concentrations at a sawmill. Occupational and Environmental Medicine, 51(3), 165-172. Abstract.
Halpin DMG, Hodson ME, Geddes DM (1992). Sex of children born to women with cystic fibrosis. The Lancet, 339(8799).
Sorrell M, Halpin DMG (1991). Art and neurology. The British Journal of Aesthetics, 31(3), 241-250.
Halpin DMG, Burrin JM, Joplin GF (1990). Serum testosterone levels in women with Cushing's disease. Acta Endocrinologica, 122(1), 71-75. Abstract.
Halpin DM, Trend P, Symon L, Harding AE (1990). Type 1 Arnold-Chiari malformation in a 77 year old woman. J Neurol Neurosurg Psychiatry, 53(1), 88-89. Author URL.
Halpin D, Wessely S (1989). VP-1 antigen in chronic postviral fatigue syndrome. Lancet, 1(8645), 1028-1029. Author URL.
Halpin DMG, Charlton HM (1988). Effects of short-term injection of gonadotrophins on ovarian follicle development in hypogonadal (hpg) mice. Journal of Reproduction and Fertility, 82(1), 393-400. Abstract.
Higgins JRA, Halpin DMG, Midgley AK (1988). Tension pneumoperitoneum: a surgical emergency. British Journal of Hospital Medicine, 39(2), 160-161.
Higgins JRA, Halpin DMG, Kapff PD (1987). Penetrating injury on an artificial ski slope. Injury, 18(5), 342-343.
Halpin DMG, Charlton HM, Faddy MJ (1986). Effects of gonadotrophin deficiency on follicular development in hypogonadal (hpg) mice. Journal of Reproduction and Fertility, 78(1), 119-125.
Halpin DMG, Jones A, Fink G, Charlton HM (1986). Postnatal ovarian follicle development in hypogonadal (hpg) and normal mice and associated changes in the hypothalamic-pituitary ovarian axis. Journal of Reproduction and Fertility, 77(1), 287-296.
Hume DA, Halpin D, Charlton H, Gordon S (1984). The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80: macrophages of endocrine organs. Proc Natl Acad Sci U S A, 81(13), 4174-4177. Abstract.  Author URL.
Charlton HM, Speight A, Halpin DMG, Bramwell A, Sheward WJ, Fink G (1983). Prolactin measurements in normal and hypogonadal (hpg) mice: Developmental and experimental studies. Endocrinology, 113(2), 545-548. Abstract.
Charlton HM, Halpin DMG, Iddon C, Rosie R, Levy G, McDowell IFW, Megson A, Morris JF, Bramwell A, Speight A, et al (1983). The effects of daily administration of single and multiple injections of gonadotropin-releasing hormone on pituitary and gonadal function in the hypogonadal (hpg) mouse. Endocrinology, 113(2), 535-544. Abstract.
Charlton HM, Parry D, Halpin DMG, Webb R (1982). Distribution of <sup>125</sup>I-labelled follicle-stimulating hormone and human chorionic gonadotrophin in the gonads of hypogonadal (hpg) mice. Journal of Endocrinology, 93(2), 247-252. Abstract.
Charlton HM, Fink G, Halpin DMG (1981). The effects of multiple injections of gonadotrophin-releasing hormone (GnRH) in the hypogonadal mouse. Journal of Physiology, Vol.320

Chapters

Halpin D, Cooper C, Leach R (2014). Chronic Obstructive Pulmonary Disease. In  (Ed) Oxford Desk Reference: Acute Medicine, Oxford University Press. Abstract.
Halpin D (2011). COPD. In  (Ed) Advanced Respiratory Critical Care, Oxford University Press. Abstract.
Halpin D, Bakere H (2011). Pneumonia. In  (Ed) Advanced Respiratory Critical Care, Oxford University Press. Abstract.
Halpin D (2009). COPD pathophysiology. In  (Ed) Oxford Desk Reference: Respiratory Medicine, Oxford University Press. Abstract.
Halpin D (2001). Chronic Obstructive Pulmonary Disease. In  (Ed) Respiratory Medicine, CRC Press. Abstract.
Halpin D, Geddes D (1994). Rheumatoid arthritis and connective tissue associated obliterative bronchiolitis. In  (Ed) Diseases of the Bronchioles, Lippincott Williams & Wilkins.
Halpin D (1992). Blood glucose homeostasis. In  (Ed) PHYSIOLOGY SURGICAL PRACTICE, CRC Press. Abstract.
Halpin D (1992). Growth and development. In  (Ed) PHYSIOLOGY SURGICAL PRACTICE, CRC Press. Abstract.
Halpin D (1992). Puberty, the menstrual cycle and the menopause. In  (Ed) PHYSIOLOGY SURGICAL PRACTICE, CRC Press. Abstract.
Halpin D (1992). Tests of endocrine function. In  (Ed) PHYSIOLOGY SURGICAL PRACTICE, CRC Press. Abstract.
Halpin D, Collins JV (1990). Bronchoscopy. In  (Ed) Respiratory Medicine, W.B. Saunders Company. Abstract.

Conferences

Thompson P, Criner G, Halpin D, Halpin M, Jones C, Kilbride S, Lipson D, Maghzal G, Martinez F, Singh D, et al (2021). EFFECT OF CHRONIC MUCUS HYPERSECRETION ON COPD OUTCOMES: IMPACT TRIAL.  Author URL.
Bratton D, Hartley B, Barnes N, Brusselle G, Compton C, Corbridge T, Dransfield M, Halpin D, Han M, Jones CE, et al (2020). BENEFIT-RISK PROFILES OF FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) VS UMEC/VI IN PATIENTS WITH COPD: a MARKOV MODEL.  Author URL.
Criner G, Barnes N, Brusselle G, Compton C, Dransfield M, Halpin D, Lan M, Christine H, Jones E, Kaye M, et al (2020). DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS EXPERIENCING ON-TREATMENT EXACERBATIONS, ON-TREATMENT DEATH, OR PREMATURE STUDY TREATMENT WITHDRAWAL: THE IMPACT TRIAL.  Author URL.
Thompson P, Criner G, Halpin D, Han M, Jones C, Killbride S, Lipson D, Maghzal G, Martinez F, Singh D, et al (2020). EFFECT OF CHRONIC MUCUS HYPERSECRETION ON COPD OUTCOMES: IMPACT TRIAL.  Author URL.
Halpin D, Korn S, Matucci A, Bourdin A, Daizadeh N, Ortiz B, Djandji M, Deniz Y, Rowe P (2020). EFFICACY OF DUPILUMAB IN PATIENTS WITH ASTHMA WITH/WITHOUT SUBSTANTIAL REDUCTION IN FRACTIONAL EXHALED NITRIC OXIDE.  Author URL.
Maspero JF, Halpin DMG, Jackson D, Hanania NA, Castro M, Domingo C, Daizadeh N, Djandji M, Rowe P, Deniz Y, et al (2020). Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function.  Author URL.
Compton C, Worsley S, Midwinter D, Ismaila A, Beeh K-M, Di Boscio V, Kocks J, Marin JM, Tabberer M, Snowise NG, et al (2020). INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata.  Author URL.
Halpin DM, Worsley S, Ismaila AS, Astrom J, Beeh KM, Brintziki D, Di Boscio V, Kocks J, Marin JM, Tabberer M, et al (2020). Intrepid: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice.  Author URL.
Calverley P, Celli B, Crim C, Dransfield M, Halpin D, Han ML, Jones CE, Kilbride S, Lange P, Lettis S, et al (2020). RISK OF DEATH AND COPD HOSPITALIZATION WITH FLUTICASONE FUROATE-CONTAINING THERAPY: POST HOC SUBGROUP ANALYSIS FROM THE SUMMIT TRIAL IN PATIENTS WITH COPD AND a HISTORY OF EXACERBATION.  Author URL.
Dransfield M, Halpin D, Han ML, Hartley B, Jones CE, Kalhan R, Kilbride S, Kunisaki K, Lange P, Lipson D, et al (2020). TIME-DEPENDENT RISK OF CARDIOVASCULAR EVENTS FOLLOWING AN EXACERBATION IN PATIENTS WITH COPD: POST HOC ANALYSIS FROM THE IMPACT TRIALl.  Author URL.
Bafadhel M, Barnes N, Bourke S, Compton C, Criner G, Dransfield M, Halpin D, Han M, Hartley B, Jones CE, et al (2019). Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD?.  Author URL.
Hanania N, Wise R, Feldman G, Siler T, Halpin D, Han M, Lipson D, Kilbride S, Jones CE, Shostak L, et al (2019). COMPARISON BETWEEN FF/UMEC/VI VS UMEC/VI AND FF/VI AND UMEC/VI VS FF/VI BASED ON BASELINE EXACERBATION HISTORY AND FEV1: SUB-ANALYSIS FROM THE IMPACT TRIAL.  Author URL.
Stiegler MA, Thomashow B, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, et al (2019). COPD Assessment Test (CAT) Score is Associated with Risk of Future Exacerbation: an Analysis from the IMPACT Trial.  Author URL.
Kerkhof M, Chaudhry I, Kocks J, Pavord I, Halpin D, Usmani O, Morris T, Alacqua M, Price D (2019). Disease Severity of Patients with High Blood Eosinophil Counts Treated for COPD Exacerbation with or Without Oral Corticosteroids.  Author URL.
Hanania N, Mannino D, Criner G, Dransfield M, Han M, Jones CE, Kilbride S, Lomas D, Martinez F, Singh D, et al (2019). EFFECT OF AGE ON EFFICACY AND SAFETY OF ONCE-DAILY SINGLE-INHALER TRIPLE THERAPY FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL IN PATIENTS WITH COPD: a POST-HOC ANALYSIS OF THE IMPACT TRIAL.  Author URL.
Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, et al (2019). InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: an Analysis Based on Baseline COPD Medication Use.  Author URL.
Han MK, Criner GJ, Dransfield MT, Halpin DMG, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, Martinez FJ, et al (2019). Preventing Clinically Important Deterioration (CID) of COPD with Single-inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol: a Prospective Analysis of the IMPACT Trial.  Author URL.
Lipson DA, Criner G, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Cardiovascular Safety.  Author URL.
Kaisermann MC, Criner GJ, Dransfield MT, Halpin DM, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Rescue Use and Night-Time Awakenings.  Author URL.
Criner GJ, Dransfield M, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez F, Pascoe S, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: a Pre-Specified Analysis of Safety According to Age.  Author URL.
Halpin DMG, Bardsley S, Criner G, Dransfield M, Han MK, Jones CE, Kilbride S, Lomas DA, Martinez F, Pascoe S, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Analysis According to Smoking Status.  Author URL.
Han MK, Criner G, Dransfield M, Halpin D, Jones CE, Kilbride S, Lange P, Lomas D, Martinez F, Quasny H, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Consistent benefit across multiple exacerbation endpoints.  Author URL.
Lipson DA, Criner G, Dransfield M, Halpin D, Han M, Jones CE, Kilbride S, Lange P, Lomas D, Martinez F, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time.  Author URL.
Han MK, Halpin DM, Martinez FJ, Miravitlles M, Singh D, de la Hoz A, Voss F, Rabe F (2018). A Composite Endpoint of Clinically Important Deterioration in Chronic Obstructive Pulmonary Disease and its Association with Increased Mortality: a Post Hoc Analysis of the UPLIFT Study.  Author URL.
Halpin DMG, de Jong H, Carter V, Skinner D, Price D (2018). CHARACTERISTICS OF ESTABLISHED AND NEWLY TREATED PATIENTS WITH COPD ACCORDING TO GOLD 2017 IN a UK PRIMARY CARE POPULATION.  Author URL.
Halpin D, Hamelmann E, Moroni-Zentgraf P, Van Hecke B, Unseld A, Kerstjens H (2018). COMPARATIVE RESPONSES IN LUNG FUNCTION MEASUREMENTS IN MODERATE SYMPTOMATIC ASTHMA.  Author URL.
Lipson DA, Barnhart F, Boucot I, Crim C, Brealey N, Criner GJ, Dransfield M, Halpin DMG, Kilbride S, Han MK, et al (2018). Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial.  Author URL.
Singh D, Barnhart F, Brealey N, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, et al (2018). FF/UMEC/VI versus FF/VI and UMEC/VI in the ELLIPTA device in patients with COPD: Subgroup analyses from the IMPACT trial.  Author URL.
Frith P, Halpin D, Moroni-Zentgraf P, van Hecke B, Sigmund R, Kerstjens H (2018). FVC RESPONSE TO TIOTROPIUM RESPIMAT (R) IN ADULTS WITH SYMPTOMATIC ASTHMA.  Author URL.
Singh D, Criner G, Day NC, Dransfield M, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, et al (2018). Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening.  Author URL.
Pascoe S, Barnes N, Brusselle G, Compton C, Criner G, Dransfield M, Halpin DMG, Han MK, Hartley B, Hilton E, et al (2018). Late Breaking Abstract - Blood eosinophil counts and treatment response in COPD: analyses of IMPACT.  Author URL.
Halpin DMG, De Jong H, Carter V, Skinner D, Price D (2018). Prevalence of comorbidities in established and newly treated patients with COPD according to GOLD 2017 in a UK primary care population.  Author URL.
Dransfield M, Crim C, Criner G, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, et al (2018). RISK OF EXACERBATION AND PNEUMONIA WITH SINGLE INHALER TRIPLE VERSUS DUAL THERAPY IN IMPACT.  Author URL.
Lipson DA, Barnhart F, Brealey N, Day NC, Brooks J, Criner G, Dransfield MT, Halpin DM, Han MK, Jones C, et al (2018). Reduction in All-Cause Mortality with Single Inhaler Triple Therapy (FF/UMEC/VI) Versus Dual Therapy (FF/VI and UMEC/VI) in Symptomatic Patients with COPD: Prespecified Analysis of the Phase III IMPACT Trial.  Author URL.
Lipson DA, Barnhart F, Brealey N, Day NC, Brooks J, Criner G, Dransfield MT, Halpin DM, Han MK, Jones C, et al (2018). Single Inhaler Triple-Therapy (ICS/LAMA/LABA) Versus Dual-Therapy (ICS/LABA or LAMA/LABA) in Patients with COPD at Risk of Exacerbations: Efficacy and Safety Results of the Phase III IMPACT Trial.  Author URL.
Dransfield M, Halpin D, Barnacle H, Mohrlang C, Birk R, Brealey N, Zhu C-Q, Lipson D (2018). Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes.  Author URL.
FitzGerald JM, Buhl R, Casale TB, Engel M, Sigmund R, Halpin DM (2018). TIOTROPIUM RESPIMAT (R) REDUCES EPISODES OF ASTHMA WORSENING IN PRIMOTINA-ASTHMA (R), IRRESPECTIVE OF BASELINE CHARACTERISTICS OR SEASON.  Author URL.
FitzGerald JM, Buhl R, Casale TB, El Azzi G, Engel M, Sigmund R, Halpin DM (2018). Tiotropium Respimat (R) Reduces Episodes of Asthma Worsening in PrimoTinA-asthma (R), Irrespective of Baseline Characteristics or Season.  Author URL.
Halpin D, Hamelmann E, Moroni-Zentgraf P, Van Hecke B, Unseld A, Kerstjens H (2017). COMPARATIVE RESPONSES IN LUNG FUNCTION MEASUREMENTS IN ADOLESCENTS AND ADULTS WITH MODERATE SYMPTOMATIC ASTHMA.  Author URL.
Martinez F, Halpin D, Han MK, MiravitIes M, Rabe KF, Groenke L, Voss F, Singh D (2017). Clinically Important Deterioration Events in Chronic Obstructive Pulmonary Disease: a Post Hoc Analysis of the Relative Timing of Component Deterioration in the Uplift Study.  Author URL.
Frith P, Halpin D, Moroni-Zentgraf P, Van Hecke B, Sigmund R, Kerstjens H (2017). FORCED VITAL CAPACITY RESPONSE TO TIOTROPIUM RESPIMAT (R) IN ADULT PATIENTS WITH SEVERE, MODERATE AND MILD SYMPTOMATIC ASTHMA.  Author URL.
Hilton E, Brealey N, Birk R, Zhu C-Q, Criner GJ, Dransfield MT, Halpin D, Lomas DA, Lipson DA (2017). IMPROVEMENTS IN EXACERBATION RATES WITH SINGLE INHALER TRIPLE THERAPY VERSUS DUAL ICS/LABA THERAPY IN PATIENTS WITH ADVANCED CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): SUBGROUP ANALYSES OF THE PHASE III FULFIL STUDY.  Author URL.
Vogelberg C, Halpin D, Voelker B, Engel M, Luehmann R, Hamelmann E (2017). Once-daily tiotropium Respimat add-on therapy improves lung function in children with moderate symptomatic asthma, independent of the degree of airflow obstruction.  Author URL.
Rabe KF, Halpin D, Martinez F, Miravitlles M, Singh D, Groenke L, Voss F, Han MK (2017). Predicting Long-Term Outcomes and Future Deterioration in COPD with a Composite Endpoint: Post Hoc Analysis of the Uplift Study.  Author URL.
Halpin D, Han MK, Martinez F, Rabe KF, Singh D, Groenke L, Voss F, Miravitlles M (2017). Time-To-Event Analysis of a Composite Endpoint for Chronic Obstructive Pulmonary Disease: Post Hoc Analysis of the Uplift Study.  Author URL.
Casale TB, Halpin DM, Engel M, Moroni-Zentgraf P, Muller A, Beeh K-M (2015). 24-HOUR EFFICACY OF TIOTROPIUM RESPIMAT (R) IN ASTHMA.  Author URL.
Halpin D, Bateman ED, Paggiaro P, Bleecker ER, Engel M, Moroni-Zentgraf P, Schmidt H, Kerstjens HAM (2015). ONCE-DAILY TIOTROPIUM RESPIMAT (R) ADD-ON TO AT LEAST ICS MAINTENANCE THERAPY REDUCES EXACERBATION RISK IN PATIENTS WITH UNCONTROLLED SYMPTOMATIC ASTHMA.  Author URL.
Chamberlain C, Williamson GR, Knight B, Daly M, Halpin DMG (2014). Investigating women’s experiences of asthma care in pregnancy: a qualitative study.  Abstract.
Tashkin DP, Li N, Kleerup E, Halpin D, Decramer M, Celli BR, Elashoff R (2014). Long-Term Trends in Acute Bronchodilator Responses over 4 Years in Patients with Mild/moderate to Very Severe COPD: Post-Hoc Analysis of Data from the Uplift Trial.  Author URL.
Halpin DMG, Paggiaro P, Bleecker E, Engel M, Moroni-Zentgraf P, Schmidt H, Kerstjens HAM (2014). ONCE-DAILY TIOTROPIUM RESPIMAT (R) ADD-ON TO AT LEAST ICS MAINTENANCE THERAPY REDUCES EXACERBATION RISK IN PATIENTS WITH UNCONTROLLED SYMPTOMATIC ASTHMA.  Author URL.
Halpin D, Bateman E, Paggiaro P, Bleecker E, Engel M, Moroni-Zentgraf P, Schmidt H, Kerstjens H (2014). Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma.  Author URL.
Halpin D, Bateman E, Paggiaro P, Bleecker E, Engel M, Moroni-Zentgraf P, Schmidt H, Kerstjens H (2014). Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma.  Author URL.
Halpin DMG, Dahl R, Hallmann C, Leimer I, Mueller A, Tashkin DP (2014). TIOTROPIUM HANDIHALER (R) AND RESPIMAT (R) IN COPD: a SAFETY ANALYSIS ON POOLED DATA.  Author URL.
Paggiaro P, Halpin DMG, Buhl R, Engel M, Zubek VB, Blahova Z, Moroni-Zentgraf P, Pizzichini E (2014). TIOTROPIUM RESPIMAT (R) ADD-ON TO INHALED CORTICOSTEROIDS IMPROVES LUNG FUNCTION IN PATIENTS WITH SYMPTOMATIC MILD ASTHMA: RESULTS FROM a PHASE III TRIAL.  Author URL.
Halpin DMG, Dahl R, Hallmann C, Leimer I, Kupas K, Mueller A, Tashkin DP (2014). Tiotropium Handihaler (R) and Respimat (R) in COPD: a Safety Analysis on Pooled Data.  Author URL.
Paggiaro P, Halpin DMG, Buhl R, Engel M, Zubek V, Blahova Z, Moroni-Zentgraf P, Pizzichini E (2014). Tiotropium Respimat (R) Add-On to Inhaled Corticosteroids Improves Lung Function in Patients with Symptomatic Mild Asthma: Results from a Phase III Trial.  Author URL.
Tashkin DP, Li N, Halpin D, Kleerup E, Decramer M, Celli BR, Elashoff R (2013). Comparison of the Annual Rates of Change in Fev1 and FVC Determined from Serial Measurements of the Pre- Vs. Post-Bronchodilator Fev1 and FVC over 4 Years in Moderate Yo Very Severe COPD: Results from the Uplift Trial.  Author URL.
Decramer M, Celli BR, Tashkin DP, Martin A, Leimer I, Metzdorf N, Halpin DM (2013). Efficacy of Tiotropium in a 4 Years Study Analyzed According to New Gold Abcd Severity Grading.  Author URL.
Halpin DMG, Holmes S, Calvert J, McInerney D (2013). FINDING THE MISSING MILLIONS: CASE FINDING FOR COPD IN PEOPLE ATTENDING OTHER LONG TERM CONDITION CLINICS IN PRIMARY CARE.  Author URL.
Chamberlain C, Williamson GR, Knight B, Daley M, Halpin DM (2013). INVESTIGATING WOMEN'S EXPERIENCES OF ASTHMA CARE IN PREGNACY: a QUALITATIVE STUDY.  Author URL.
Bernstein JA, Kerstjens HAM, Moroni-Zentgraf P, Engel M, Schmidt H, Halpin DMG (2013). Once-Daily Tiotropium is Well Tolerated as Add-On to Standard Treatment for Patients with Symptomatic Asthma Despite Receiving Inhaled Corticosteroids and Long-Acting beta(2)-Agonists.  Author URL.
Halpin DMG (2013). PREVALENCE OF SERUM EOSINOPHILIA AT TIME OF ADMISSION WITH AN EXACERBATION OF COPD.  Author URL.
Halpin DMG, Bateman ED, Tashkin DP, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, Seibold W, Moroni-Zentgraf P, et al (2013). TIOTROPIUM DECREASES THE RISK OF EXACERBATIONS IN PATIENTS WITH SYMPTOMATIC ASTHMA REGARDLESS OF BASELINE CHARACTERISTICS INCLUDING MARKERS OF ALLERGIC STATUS.  Author URL.
Halpin DMG, Bateman ED, Moroni-Zentgraf P, Engel M, Schmidt H, Kerstjens HAM (2013). TIOTROPIUM IS EFFECTIVE IN PATIENTS WITH SEVERE ASTHMA WITHOUT EVIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE.  Author URL.
Halpin DM, Bateman ED, Moroni-Zentgraf P, Engel M, Schmidt H, Kerstjens HAM (2013). Tiotropium is Effective in Patients with Severe Asthma Without Evidence of Chronic Obstructive Pulmonary Disease.  Author URL.
Halpin DMG, Batten P, Chamberlain C (2012). COPD DISCHARGE BUNDLES: THE EXETER EXPERIENCE 2011-12.  Author URL.
Halpin D, Decramer M, Celli B, Martin A, Leimer I, Metzdorf N, Tashkin D (2012). Effectiveness of tiotropium in low-risk patients according to new GOLD severity grading.  Author URL.
Halpin D, Decramer M, Celli B, Martin A, Leimer I, Metzdorf N, Tashkin D (2012). Impact of a single chronic obstructive pulmonary disease (COPD) exacerbation on lung function decline: Analysis of UPLIFT (R).  Author URL.
Dodd JW, Tribe HC, Halpin DM (2007). Appropriateness of emergency oxygen therapy for COPD patients.  Author URL.
Halpin DMG, Miravitlles M (2006). Chronic obstructive pulmonary disease: the disease and its burden to society.  Abstract.
Halpin DMG (2006). Health economics of chronic obstructive pulmonary disease.  Abstract.
Bryden C, Bird W, Halpin DM, Levy ML (2006). Seasonality in chronic obstructive pulmonary disease emergency admissions to hospital, and predictability using surveillance for influenza-like illness.  Author URL.

Publications by year


2021

Bafadhel M, Barnes N, Bourke SC, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MLK, Hartley B, Jones CE, et al (2021). A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. European Respiratory Journal, 58(3).
Bousquet J, Jutel M, Akdis CA, Klimek L, Pfaar O, Nadeau KC, Eiwegger T, Bedbrook A, Ansotegui IJ, Anto JM, et al (2021). ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy, 76(3), 689-697. Author URL.
Mammen MJ, Carr TF, Kraft M, Criner GJ, Dransfield MT, Wells JM, Halpin DMG, Han MK, Jain RG, Kaul V, et al (2021). All-cause mortality by subgroup in patients with chronic obstructive pulmonary disease: Post hoc analysis of the impact trial. Am. J. Respir. Crit. Care Med., 203(9). Abstract.  Author URL.
Wells JM, Bhatt SP, Dransfield MT, Carr TF, Kraft M, Criner GJ, Halpin DMG, Han MK, Jain R, Kaye MG, et al (2021). An analysis of the impact trial assessing single-inhaler therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI using a composite adverse event outcome in patients with copd. Am. J. Respir. Crit. Care Med., 203(9). Abstract.  Author URL.
Bourbeau J, Bafadhel M, Barnes NC, Compton C, Di Boscio V, Lipson DA, Jones PW, Martin N, Weiss G, Halpin DMG, et al (2021). Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 16, 499-517. Author URL.
Halpin DMG, Vogelmeier CF, Agusti AA (2021). COPD & COVID-19. ARCHIVOS DE BRONCONEUMOLOGIA, 57(3), 162-164. Author URL.
Bousquet J, Anto JM, Czarlewski W, Haahtela T, Fonseca SC, Iaccarino G, Blain H, Vidal A, Sheikh A, Akdis CA, et al (2021). Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. ALLERGY, 76(3), 735-750. Author URL.
Thompson P, Criner G, Halpin D, Halpin M, Jones C, Kilbride S, Lipson D, Maghzal G, Martinez F, Singh D, et al (2021). EFFECT OF CHRONIC MUCUS HYPERSECRETION ON COPD OUTCOMES: IMPACT TRIAL.  Author URL.
Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MLK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, et al (2021). Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD: a Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. Chest, 159(3), 985-995. Abstract.
Halpin DMG, Vogelmeier CF, Mezzi K, Gupta P, Kostikas K, Wedzicha JA (2021). Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of ignite trials. ERJ Open Research, 7(1). Abstract.
Han MK, Agusti A, Celli BR, Criner GJ, Halpin DMG, Roche N, Papi A, Stockley RA, Wedzicha J, Vogelmeier CF, et al (2021). From GOLD 0 to Pre-COPD. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 203(4), 414-423. Author URL.
Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, Agusti AA, Vogelmeier CF (2021). Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. American Journal of Respiratory and Critical Care Medicine, 203(1), 24-36. Abstract.
Meghji J, Mortimer K, Agusti A, Allwood BW, Asher I, Bateman ED, Bissell K, Bolton CE, Bush A, Celli B, et al (2021). Improving lung health in low-income and middle-income countries: from challenges to solutions. LANCET, 397(10277), 928-940. Author URL.
Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Lange P, Lettis S, Lipson DA, Mannino D, Martin N, et al (2021). InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. RESPIRATORY RESEARCH, 22(1). Author URL.
Price D, Jones R, Pfister P, Cao H, Carter V, Kemppinen A, Holzhauer B, Kaplan A, Clark A, Halpin DMG, et al (2021). Maximizing Adherence and Gaining New Information for Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes. Pragmat Obs Res, 12, 25-35. Abstract.  Author URL.
Mahler DA, Halpin DMG (2021). Peak Inspiratory Flow as a Predictive Therapeutic Biomarker in COPD. CHEST, 160(2), 491-498. Author URL.
Han MK, Agusti A, Celli BR, Criner GJ, Halpin DMG, Roche N, Papi A, Stockley RA, Wedzicha J, Vogelmeier CF, et al (2021). Pre-Chronic Obstructive Pulmonary Disease: Toward the Limits of the Spirometric Funnel Reply. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 204(1), 112-112. Author URL.
Han MK, Criner GJ, Dransfield MT, Halpin DMG, Jones CE, Kilbride S, Lange P, Lettis S, Lipson DA, Lomas DA, et al (2021). Prognostic value of clinically important deterioration in copd: Impact trial analysis. ERJ Open Research, 7(1). Abstract.
Humbert M, Bourdin A, Papadopoulos NG, Holgate ST, Hanania NA, Halpin DMG, Chapman KR, Gavornikova M, Price DB, Kaplan A, et al (2021). Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. JOURNAL OF ASTHMA, 58(7), 849-854. Author URL.
Mapel DW, Bogart M, Jain R, Criner GJ, Dransfield MT, Gaeckle N, Gotfried M, Halpin DMG, Han MK, Kaul V, et al (2021). Reduction in emergency department (ED) visits in patients with chronic obstructive pulmonary disease (Copd): Analysis of the impact trial. Am. J. Respir. Crit. Care Med., 203(9). Abstract.  Author URL.
Jones R, Davis A, Stanley B, Julious S, Ryan D, Jackson DJ, Halpin DMG, Hickman K, Pinnock H, Quint JK, et al (2021). Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. Pragmat Obs Res, 12, 93-104. Abstract.  Author URL.
Mammen MJ, Carr TF, Kraft M, Criner GJ, Dransfield MT, Wells JM, Halpin DMG, Han MK, Hartley B, Jain R, et al (2021). Risk of all-cause mortality during and after severe exacerbations in patients with chronic obstructive pulmonary disease (Copd): Post hoc analysis of the impact trial. Am. J. Respir. Crit. Care Med., 203(9). Abstract.  Author URL.
Dransfield MT, Crim C, Criner GJ, Day NC, Halpin DMG, Han MLK, Elaine Jones C, Kilbride S, LaFon D, Lipson DA, et al (2021). Risk of exacerbation and pneumonia with single-inhaler triple versus dual therapy in IMPACT. Annals of the American Thoracic Society, 18(5), 788-798. Abstract.
Corbetta L, Fabbri LM, Halpin D, Cruz AA, Zanconato S (2021). Stand on the Same Side Against Covid – 19: Ics-Containing Products in Treatment Covid-19 Patients with Asthma and COPD. Substantia, 1234-1234. Abstract.
Halpin DMG, Criner GJ, Dransfield MT, Han MLK, Hartley B, Harvey C, Jones CE, Kato M, Lange P, Lettis S, et al (2021). Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. Pulmonary Therapy, 7(1), 101-118. Abstract.

2020

Ming SWY, Haughney J, Ryan D, Small I, Lavorini F, Papi A, Singh D, Halpin DMG, Hurst JR, Patel S, et al (2020). A comparison of the real-life clinical effectiveness of the leading licensed ics/laba combination inhalers in the treatment for copd. International Journal of COPD, 15, 3093-3103. Abstract.
To T, Viegi G, Cruz A, Taborda-Barata L, Asher I, Behera D, Bennoor K, Boulet L-P, Bousquet J, Camargos P, et al (2020). A global respiratory perspective on the COVID-19 pandemic: commentary and action proposals. Eur Respir J, 56(1). Author URL.
Bratton D, Hartley B, Barnes N, Brusselle G, Compton C, Corbridge T, Dransfield M, Halpin D, Han M, Jones CE, et al (2020). BENEFIT-RISK PROFILES OF FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) VS UMEC/VI IN PATIENTS WITH COPD: a MARKOV MODEL.  Author URL.
Kerkhof M, Chaudhry I, Pavord ID, Miravitlles M, Kook Rhee C, Halpin DMG, Usmani OS, Jones R, Kocks J, Alacqua M, et al (2020). Blood eosinophil count predicts treatment failure and hospital readmission for COPD. ERJ Open Res, 6(4). Abstract.  Author URL.
(2020). COVID-19 pandemic alert: time to focus on lung health-Beijing call to action for lung health promotion. Journal of Thoracic Disease, 12(6), 3238-3241.
Rabe KF, Halpin DMG, Han MK, Miravitlles M, Singh D, Groenke L, Voss F, Martinez FJ (2020). Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. RESPIRATORY RESEARCH, 21(1). Author URL.
Criner G, Barnes N, Brusselle G, Compton C, Dransfield M, Halpin D, Lan M, Christine H, Jones E, Kaye M, et al (2020). DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS EXPERIENCING ON-TREATMENT EXACERBATIONS, ON-TREATMENT DEATH, OR PREMATURE STUDY TREATMENT WITHDRAWAL: THE IMPACT TRIAL.  Author URL.
Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A (2020). Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?. The Lancet Respiratory Medicine, 8(5), 436-438.
Thompson P, Criner G, Halpin D, Han M, Jones C, Killbride S, Lipson D, Maghzal G, Martinez F, Singh D, et al (2020). EFFECT OF CHRONIC MUCUS HYPERSECRETION ON COPD OUTCOMES: IMPACT TRIAL.  Author URL.
Halpin D, Korn S, Matucci A, Bourdin A, Daizadeh N, Ortiz B, Djandji M, Deniz Y, Rowe P (2020). EFFICACY OF DUPILUMAB IN PATIENTS WITH ASTHMA WITH/WITHOUT SUBSTANTIAL REDUCTION IN FRACTIONAL EXHALED NITRIC OXIDE.  Author URL.
Maspero JF, Halpin DMG, Jackson D, Hanania NA, Castro M, Domingo C, Daizadeh N, Djandji M, Rowe P, Deniz Y, et al (2020). Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function.  Author URL.
Compton C, Worsley S, Midwinter D, Ismaila A, Beeh K-M, Di Boscio V, Kocks J, Marin JM, Tabberer M, Snowise NG, et al (2020). INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata.  Author URL.
Kaplan A, Szefler SJ, Halpin DMG (2020). Impact of comorbid conditions on asthmatic adults and children. npj Primary Care Respiratory Medicine, 30(1). Abstract.
Singh D, Halpin DMG (2020). Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying?. The Lancet Respiratory Medicine, 8(11), 1065-1066.
Halpin DMG, Singh D, Hadfield RM (2020). Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. EUROPEAN RESPIRATORY JOURNAL, 55(5). Author URL.
Halpin DM, Worsley S, Ismaila AS, Astrom J, Beeh KM, Brintziki D, Di Boscio V, Kocks J, Marin JM, Tabberer M, et al (2020). Intrepid: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice.  Author URL.
Halpin DM, Worsley S, Ismaila AS, Astrom J, Beeh KM, Brintziki D, Tabberer M, Di Boscio V, Compton C, Kocks J, et al (2020). Intrepid: Clinical effectiveness of once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol versus multiple-inhaler triple therapy in usual clinical practice. Am. J. Respir. Crit. Care Med., 201(1). Abstract.  Author URL.
Bousquet J, Cristol JP, Czarlewski W, Anto JM, Martineau A, Haahtela T, Fonseca SC, Iaccarino G, Blain H, Fiocchi A, et al (2020). Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. Clinical and Translational Allergy, 10(1). Abstract.
Calverley P, Celli B, Crim C, Dransfield M, Halpin D, Han ML, Jones CE, Kilbride S, Lange P, Lettis S, et al (2020). RISK OF DEATH AND COPD HOSPITALIZATION WITH FLUTICASONE FUROATE-CONTAINING THERAPY: POST HOC SUBGROUP ANALYSIS FROM THE SUMMIT TRIAL IN PATIENTS WITH COPD AND a HISTORY OF EXACERBATION.  Author URL.
Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, et al (2020). Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 201(12), 1508-1516. Abstract.  Author URL.
Tabberer M, Jones CE, Kilbride S, Halpin DMG, Lomas DA, Pascoe S, Singh D, Wise RA, Criner GJ, Lange P, et al (2020). Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: the IMPACT Study. Advances in Therapy, 37(9), 3775-3790. Abstract.
Day NC, Kumar S, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kaisermann MC, Kilbride S, Lange P, et al (2020). Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: Results on cardiovascular safety from the IMPACT trial. Respiratory Research, 21(1). Abstract.
Dransfield M, Halpin D, Han ML, Hartley B, Jones CE, Kalhan R, Kilbride S, Kunisaki K, Lange P, Lipson D, et al (2020). TIME-DEPENDENT RISK OF CARDIOVASCULAR EVENTS FOLLOWING AN EXACERBATION IN PATIENTS WITH COPD: POST HOC ANALYSIS FROM THE IMPACT TRIALl.  Author URL.
Halpin DMG, Dransfield MT, Han MLK, Elaine Jones C, Kilbride S, Lange P, Lipson DA, Lomas DA, Martinez FJ, Pascoe S, et al (2020). The effect of exacerbation history on outcomes in the impact trial. European Respiratory Journal, 55(6). Abstract.
Han MLK, Criner GJ, Dransfield MT, Halpin DMG, Elaine Jones C, Kilbride S, Lange P, Lettis S, Lipson DA, Lomas DA, et al (2020). The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study a randomized, double-blind, multicenter clinical trial. American Journal of Respiratory and Critical Care Medicine, 202(9), 1237-1243. Abstract.
FitzGerald JM, Buhl R, Casale TB, Jugovic B, Zaremba-Pechmann L, Halpin DMG (2020). Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma. EUROPEAN RESPIRATORY JOURNAL, 55(1). Author URL.
Halpin DMG (2020). What is Asthma Chronic Obstructive Pulmonary Disease Overlap?. Clinics in Chest Medicine, 41(3), 395-403. Abstract.

2019

Bafadhel M, Barnes N, Bourke S, Compton C, Criner G, Dransfield M, Halpin D, Han M, Hartley B, Jones CE, et al (2019). Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD?.  Author URL.
Price DB, Bosnic-Anticevich S, Pavord ID, Roche N, Halpin DMG, Bjermer L, Usmani OS, Brusselle G, Ming SWY, Rastogi S, et al (2019). Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. Clinical and Translational Allergy, 9(1). Abstract.
Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MLK, Hartley B, Lange P, et al (2019). Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. The Lancet Respiratory Medicine, 7(9), 745-756. Abstract.
Pascoe S, Barnes N, Compton C, Hilton E, Van Der Valk RJP, Brusselle G, Criner G, Dransfield M, Halpin DMG, Han MK, et al (2019). Bzlood eosinophil counts and treatment response in COPD: Analyses of IMPACT. Pneumologie, 73(SUPPPL. 1). Abstract.
Hanania N, Wise R, Feldman G, Siler T, Halpin D, Han M, Lipson D, Kilbride S, Jones CE, Shostak L, et al (2019). COMPARISON BETWEEN FF/UMEC/VI VS UMEC/VI AND FF/VI AND UMEC/VI VS FF/VI BASED ON BASELINE EXACERBATION HISTORY AND FEV1: SUB-ANALYSIS FROM THE IMPACT TRIAL.  Author URL.
Stiegler MA, Thomashow B, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, et al (2019). COPD Assessment Test (CAT) Score is Associated with Risk of Future Exacerbation: an Analysis from the IMPACT Trial.  Author URL.
Stockley RA, Halpin DMG, Celli BR, Singh D (2019). Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 199(10), 1195-1204. Author URL.
Halpin D (2019). Chronic Obstructive Pulmonary Disease and Work: is it Time to Stop?. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 200(10), 1195-1197. Author URL.
Worsley S, Snowise N, Halpin DMG, Midwinter D, Ismaila AS, Irving E, Sansbury L, Tabberer M, Leather D, Compton C, et al (2019). Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/ vilanterol in usual practice: the COPD INTREPID study design. ERJ Open Research, 5(4). Abstract.
Lipson DA, Barnhart F, Crim C, Jones CE, Boucot I, Brealey N, Kilbride S, Criner G, Dransfield M, Halpin DMG, et al (2019). Comparison of LAMA/LABA vs. ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial. Pneumologie, 73(SUPPPL. 1). Abstract.
Stockley RA, Halpin D, Celli BR, Singh D (2019). Confounding Factors Affecting sRAGE as a Biomarker for Chronic Obstructive Pulmonary Disease Reply. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 200(1), 114-115. Author URL.
Ismaila AS, Risebrough N, Schroeder M, Shah D, Martin A, Goodall EC, Ndirangu K, Criner G, Dransfield M, Halpin DMG, et al (2019). Cost-Effectiveness of Once-Daily Single-Inhaler Triple Therapy in COPD: the IMPACT Trial. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 14, 2681-2695. Author URL.
Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, et al (2019). Current Controversies in Chronic Obstructive Pulmonary Disease a Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. ANNALS OF THE AMERICAN THORACIC SOCIETY, 16(1), 29-39. Author URL.
Kerkhof M, Chaudhry I, Kocks J, Pavord I, Halpin D, Usmani O, Morris T, Alacqua M, Price D (2019). Disease Severity of Patients with High Blood Eosinophil Counts Treated for COPD Exacerbation with or Without Oral Corticosteroids.  Author URL.
Halpin DMG, de Jong HJI, Carter V, Skinner D, Price D (2019). Distribution, Temporal Stability and Appropriateness of Therapy of Patients with COPD in the UK in Relation to GOLD 2019. EClinicalMedicine, 14, 32-41. Abstract.
Hanania N, Mannino D, Criner G, Dransfield M, Han M, Jones CE, Kilbride S, Lomas D, Martinez F, Singh D, et al (2019). EFFECT OF AGE ON EFFICACY AND SAFETY OF ONCE-DAILY SINGLE-INHALER TRIPLE THERAPY FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL IN PATIENTS WITH COPD: a POST-HOC ANALYSIS OF THE IMPACT TRIAL.  Author URL.
Lipson DA, Barnhart F, Boucot I, Naya I, Crim C, Jones CE, Brealey N, Kilbride S, Criner G, Dransfield M, et al (2019). Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. Pneumologie, 73(SUPPPL. 1). Abstract.
Singh SJ, Halpin DMG, Salvi S, Kirenga BJ, Mortimer K (2019). Exercise and pulmonary rehabilitation for people with chronic lung disease in LMICs: challenges and opportunities. LANCET RESPIRATORY MEDICINE, 7(12), 1002-1004. Author URL.
Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, et al (2019). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. EUROPEAN RESPIRATORY JOURNAL, 53(5). Author URL.
Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, et al (2019). InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: an Analysis Based on Baseline COPD Medication Use.  Author URL.
Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, et al (2019). InforMing the pathway of COPD treatment (The IMPACT study): Single inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol) versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: an analysis based on baseline COPD medication use. Am. J. Respir. Crit. Care Med., 199(9). Abstract.  Author URL.
Halpin DMG, Celli BR, Criner GJ, Frith P, Victorina López Varela M, Salvi S, Vogelmeier CF, Chen R, Mortimer K, Montes de Oca M, et al (2019). It is time for the world to take COPD seriously: a statement from the GOLD board of directors. European Respiratory Journal, 54(1).
Hartley B, Criner GJ, Dransfield MT, Halpin DMG, Han MLK, Elaine Jones C, Kilbride S, Lange P, Lipson DA, Lomas DA, et al (2019). Misinterpretation of time-to-first event curves can lead to inappropriate treatment. European Respiratory Journal, 54(3).
Hartley B, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, et al (2019). Misinterpretation of time-to-first event curves can lead to inappropriate treatment. EUROPEAN RESPIRATORY JOURNAL, 54(3). Author URL.
Halpin DMG, Meltzer EO, Pisternick-Ruf W, Moroni-Zentgraf P, Engel M, Zaremba-Pechmann L, Casale T, FitzGerald JM (2019). Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV1. RESPIRATORY RESEARCH, 20 Author URL.
Han MK, Criner GJ, Dransfield MT, Halpin DMG, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, Martinez FJ, et al (2019). Preventing Clinically Important Deterioration (CID) of COPD with Single-inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol: a Prospective Analysis of the IMPACT Trial.  Author URL.
Lipson DA, Criner GJ, Day N, Kilbride S, Midwinter D, Dransfield MT, Halpin DM, Han MK, Jones C, Manchester P, et al (2019). Reduction in the risk of all-cause mortality with fluticasone furoate/umeclidinium/vilanterol compared to umeclidinium/vilanterol in IMPACT including previously missing or censored vital status data. Am. J. Respir. Crit. Care Med., 199(9). Abstract.  Author URL.
Dransfield M, Crim C, Jones CE, Criner G, Halpin DMG, Han MK, Kilbride S, Lange P, Lipson DA, Lomas DA, et al (2019). Risk of Exacerbation and Pneumonia with Single Inhaler Triple versus Dual Therapie in IMPACT. Pneumologie, 73(SUPPPL. 1). Abstract.
Halpin DMG, Celli BR, Criner GJ, Frith P, López Varela MV, Salvi S, Vogelmeier CF, Chen R, Mortimer K, Montes de Oca M, et al (2019). The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries. International Journal of Tuberculosis and Lung Disease, 23(11), 1131-1141. Abstract.
Lipson DA, Criner G, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Cardiovascular Safety.  Author URL.
Kaisermann MC, Criner GJ, Dransfield MT, Halpin DM, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Rescue Use and Night-Time Awakenings.  Author URL.
Criner GJ, Dransfield M, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez F, Pascoe S, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: a Pre-Specified Analysis of Safety According to Age.  Author URL.
Halpin DMG, Bardsley S, Criner G, Dransfield M, Han MK, Jones CE, Kilbride S, Lomas DA, Martinez F, Pascoe S, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Analysis According to Smoking Status.  Author URL.
Han MK, Criner G, Dransfield M, Halpin D, Jones CE, Kilbride S, Lange P, Lomas D, Martinez F, Quasny H, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Consistent benefit across multiple exacerbation endpoints.  Author URL.
Lipson DA, Criner G, Dransfield M, Halpin D, Han M, Jones CE, Kilbride S, Lange P, Lomas D, Martinez F, et al (2019). The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time.  Author URL.

2018

Han MK, Halpin DM, Martinez FJ, Miravitlles M, Singh D, de la Hoz A, Voss F, Rabe F (2018). A Composite Endpoint of Clinically Important Deterioration in Chronic Obstructive Pulmonary Disease and its Association with Increased Mortality: a Post Hoc Analysis of the UPLIFT Study.  Author URL.
Halpin DMG, de Jong H, Carter V, Skinner D, Price D (2018). CHARACTERISTICS OF ESTABLISHED AND NEWLY TREATED PATIENTS WITH COPD ACCORDING TO GOLD 2017 IN a UK PRIMARY CARE POPULATION.  Author URL.
Halpin D, Hamelmann E, Moroni-Zentgraf P, Van Hecke B, Unseld A, Kerstjens H (2018). COMPARATIVE RESPONSES IN LUNG FUNCTION MEASUREMENTS IN MODERATE SYMPTOMATIC ASTHMA.  Author URL.
Miravitlles M, Roche N, Cardoso J, Halpin D, Aisanov Z, Kankaanranta H, Kobližek V, Śliwiński P, Bjermer L, Tamm M, et al (2018). Chronic obstructive pulmonary disease guidelines in Europe: a look into the future. Respir Res, 19(1). Abstract.  Author URL.
Halpin DMG, FitzGerald JM, Engel M, Moroni-Zentgraf P, Sigmund R, Meltzer EO, Casale TB (2018). Comparison of PEF vs. FEV1 endpoints in trials with tiotropium in adults and adolescents with moderate or severe symptomatic asthma. J. Allergy Clin. Immunol., 141(2 Supplement 1). Abstract.
Tashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A (2018). Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT (R) trial. RESPIRATORY RESEARCH, 19 Author URL.
Lipson DA, Barnhart F, Boucot I, Crim C, Brealey N, Criner GJ, Dransfield M, Halpin DMG, Kilbride S, Han MK, et al (2018). Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial.  Author URL.
Singh D, Barnhart F, Brealey N, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, et al (2018). FF/UMEC/VI versus FF/VI and UMEC/VI in the ELLIPTA device in patients with COPD: Subgroup analyses from the IMPACT trial.  Author URL.
Frith P, Halpin D, Moroni-Zentgraf P, van Hecke B, Sigmund R, Kerstjens H (2018). FVC RESPONSE TO TIOTROPIUM RESPIMAT (R) IN ADULTS WITH SYMPTOMATIC ASTHMA.  Author URL.
Moroni-Zentgraf P, Usmani OS, Halpin DMG (2018). Inhalation Devices. CANADIAN RESPIRATORY JOURNAL, 2018 Author URL.
Singh D, Criner G, Day NC, Dransfield M, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, et al (2018). Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening.  Author URL.
Pascoe S, Barnes N, Brusselle G, Compton C, Criner G, Dransfield M, Halpin DMG, Han MK, Hartley B, Hilton E, et al (2018). Late Breaking Abstract - Blood eosinophil counts and treatment response in COPD: analyses of IMPACT.  Author URL.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, et al (2018). Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med, 378(18), 1671-1680. Abstract.  Author URL.
Halpin DMG (2018). Palliative Care for Chronic Obstructive Pulmonary Disease Signs of Progress, but Still a Long Way to Go. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 198(11), 1356-1358. Author URL.
Halpin DMG (2018). Palliative care for people with COPD: effective but underused. EUROPEAN RESPIRATORY JOURNAL, 51(2). Author URL.
Halpin DMG, De Jong H, Carter V, Skinner D, Price D (2018). Prevalence of comorbidities in established and newly treated patients with COPD according to GOLD 2017 in a UK primary care population.  Author URL.
Dransfield M, Crim C, Criner G, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, et al (2018). RISK OF EXACERBATION AND PNEUMONIA WITH SINGLE INHALER TRIPLE VERSUS DUAL THERAPY IN IMPACT.  Author URL.
Lipson DA, Barnhart F, Brealey N, Day NC, Brooks J, Criner G, Dransfield MT, Halpin DM, Han MK, Jones C, et al (2018). Reduction in All-Cause Mortality with Single Inhaler Triple Therapy (FF/UMEC/VI) Versus Dual Therapy (FF/VI and UMEC/VI) in Symptomatic Patients with COPD: Prespecified Analysis of the Phase III IMPACT Trial.  Author URL.
Rabe KF, Halpin D, Martinez F, Singh D, Han MK, Zehendner CM, Gronke L, Voss F, Miravittlles M (2018). Relative timing of clinically important deterioration and related long-term outcomes in COPD: a post hoc analysis of the UPLIFT study. Pneumologie, 72(Supplement 1). Abstract.
Lipson DA, Barnhart F, Brealey N, Day NC, Brooks J, Criner G, Dransfield MT, Halpin DM, Han MK, Jones C, et al (2018). Single Inhaler Triple-Therapy (ICS/LAMA/LABA) Versus Dual-Therapy (ICS/LABA or LAMA/LABA) in Patients with COPD at Risk of Exacerbations: Efficacy and Safety Results of the Phase III IMPACT Trial.  Author URL.
Dransfield M, Halpin D, Barnacle H, Mohrlang C, Birk R, Brealey N, Zhu C-Q, Lipson D (2018). Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes.  Author URL.
Halpin DMG, Birk R, Brealey N, Criner GJ, Dransfield MT, Hilton E, Lomas DA, Zhu CQ, Lipson DA (2018). Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses. ERJ Open Research, 4(2). Abstract.
FitzGerald JM, Buhl R, Casale TB, Engel M, Sigmund R, Halpin DM (2018). TIOTROPIUM RESPIMAT (R) REDUCES EPISODES OF ASTHMA WORSENING IN PRIMOTINA-ASTHMA (R), IRRESPECTIVE OF BASELINE CHARACTERISTICS OR SEASON.  Author URL.
Halpin DMG (2018). The role of tiotropium+olodaterol dual bronchodilator therapy in the management of chronic obstructive pulmonary disease. Tuberculosis and Respiratory Diseases, 81(1), 13-18. Abstract.
FitzGerald JM, Buhl R, Casale TB, El Azzi G, Engel M, Sigmund R, Halpin DM (2018). Tiotropium Respimat (R) Reduces Episodes of Asthma Worsening in PrimoTinA-asthma (R), Irrespective of Baseline Characteristics or Season.  Author URL.
FitzGerald JM, Buhl R, Casale TB, El Azzi G, Engel M, Sigmund R, Halpin DM (2018). Tiotropium respimat reduces episodes of asthma worsening in primotina-asthma Irrespective of Baseline Characteristics or Season. Am. J. Respir. Crit. Care Med., 197(MeetingAbstracts). Abstract.  Author URL.
Halpin DMG (2018). Understanding irrationality: the key to changing behaviours and improving management of respiratory diseases?. LANCET RESPIRATORY MEDICINE, 6(10), 737-739. Author URL.
Williamson GR, O'Connor A, Chamberlain C, Halpin D (2018). mHealth resources for asthma and pregnancy care: Methodological issues and social media recruitment. A discussion paper. J Adv Nurs, 74(10), 2442-2449. Abstract.  Author URL.

2017

Halpin D, Hamelmann E, Moroni-Zentgraf P, Van Hecke B, Unseld A, Kerstjens H (2017). COMPARATIVE RESPONSES IN LUNG FUNCTION MEASUREMENTS IN ADOLESCENTS AND ADULTS WITH MODERATE SYMPTOMATIC ASTHMA.  Author URL.
Martinez F, Halpin D, Han MK, MiravitIes M, Rabe KF, Groenke L, Voss F, Singh D (2017). Clinically Important Deterioration Events in Chronic Obstructive Pulmonary Disease: a Post Hoc Analysis of the Relative Timing of Component Deterioration in the Uplift Study.  Author URL.
Halpin DMG, Decramer M, Celli BR, Mueller A, Metzdorf N, Tashkin DP (2017). Effect of a single exacerbation on decline in lung function in COPD. Respiratory Medicine, 128, 85-91. Abstract.
Frith P, Halpin D, Moroni-Zentgraf P, Van Hecke B, Sigmund R, Kerstjens H (2017). FORCED VITAL CAPACITY RESPONSE TO TIOTROPIUM RESPIMAT (R) IN ADULT PATIENTS WITH SEVERE, MODERATE AND MILD SYMPTOMATIC ASTHMA.  Author URL.
Halpin D (2017). GOLD 2017 report brings new recommendations on assessing chronic obstructive pulmonary disease. BRITISH JOURNAL OF HOSPITAL MEDICINE, 78(3), 129-129. Author URL.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Respirology, 22(3), 575-601. Abstract.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 195(5), 557-582. Author URL.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. EUROPEAN RESPIRATORY JOURNAL, 49(3). Author URL.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. ARCHIVOS DE BRONCONEUMOLOGIA, 53(3), 128-149. Author URL.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary (vol 49, 1700214, 2017). EUROPEAN RESPIRATORY JOURNAL, 49(6). Author URL.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al (2017). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary (vol 53, pg 128, 2017). ARCHIVOS DE BRONCONEUMOLOGIA, 53(7), 411-412. Author URL.
Hilton E, Brealey N, Birk R, Zhu C-Q, Criner GJ, Dransfield MT, Halpin D, Lomas DA, Lipson DA (2017). IMPROVEMENTS IN EXACERBATION RATES WITH SINGLE INHALER TRIPLE THERAPY VERSUS DUAL ICS/LABA THERAPY IN PATIENTS WITH ADVANCED CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): SUBGROUP ANALYSES OF THE PHASE III FULFIL STUDY.  Author URL.
Halpin DMG, Miravitlles M, Metzdorf N, Celli B (2017). Impact and prevention of severe exacerbations of COPD: a review of the evidence. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 12, 2891-2908. Author URL.
Vogelberg C, Halpin D, Voelker B, Engel M, Luehmann R, Hamelmann E (2017). Once-daily tiotropium Respimat add-on therapy improves lung function in children with moderate symptomatic asthma, independent of the degree of airflow obstruction.  Author URL.
Rabe KF, Halpin D, Martinez F, Miravitlles M, Singh D, Groenke L, Voss F, Han MK (2017). Predicting Long-Term Outcomes and Future Deterioration in COPD with a Composite Endpoint: Post Hoc Analysis of the Uplift Study.  Author URL.
Halpin D, Han MK, Martinez F, Rabe KF, Singh D, Groenke L, Voss F, Miravitlles M (2017). Time-To-Event Analysis of a Composite Endpoint for Chronic Obstructive Pulmonary Disease: Post Hoc Analysis of the Uplift Study.  Author URL.
Thomas M, Halpin DMG, Miravitlles M (2017). When is dual bronchodilation indicated in COPD?. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 12, 2291-2305. Author URL.
Halpin DM, Kaplan AG, Russell RK (2017). Why choose tiotropium for my patient? a comprehensive review of actions and outcomes versus other bronchodilators. RESPIRATORY MEDICINE, 128, 28-41. Author URL.

2016

Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, Kankaanranta H, Sandström T, Śliwiński P, Zatloukal J, et al (2016). A review of national guidelines for management of COPD in Europe. Eur Respir J, 47(2), 625-637. Abstract.  Author URL.
Halpin D, Holmes S, Calvert J, McInerney D (2016). Case finding for chronic obstructive pulmonary disease in people attending long-term condition clinics in primary care. Chron Respir Dis, 13(4), 337-343. Abstract.  Author URL.
Singh D, Roche N, Halpin D, Agusti A, Wedzicha JA, Martinez FJ (2016). Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 194(5), 541-549. Abstract.  Author URL.
Lange P, Halpin DM, O'Donnell DE, MacNee W (2016). Diagnosis, assessment, and phenotyping of COPD: beyond FEV₁. International journal of chronic obstructive pulmonary disease, 11 Spec, 3-12. Abstract.
Halpin DMG, Vogelmeier C, Pieper MP, Metzdorf N, Richard F, Anzueto A (2016). Effect of tiotropium on COPD exacerbations: a systematic review. RESPIRATORY MEDICINE, 114, 1-8. Author URL.
Halpin DMG, Kerkhof M, Soriano JB, Mikkelsen H, Price DB (2016). Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. RESPIRATORY RESEARCH, 17 Author URL.
Hyland ME, Halpin DMG, Blake S, Seamark C, Pinnuck M, Ward D, Whalley B, Greaves CJ, Hawkins AL, Seamark D, et al (2016). Preference for different relaxation techniques by COPD patients: Comparison between six techniques. International Journal of COPD, 11(1), 2315-2319. Abstract.  Full text.
Dahl R, Engel M, Dusser D, Halpin D, Kerstjens HAM, Zaremba-Pechmann L, Moroni-Zentgraf P, Busse WW, Bateman ED (2016). Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: a pooled safety analysis. Respir Med, 118, 102-111. Abstract.  Author URL.
Paggiaro P, Halpin DMG, Buhl R, Engel M, Zubek VB, Blahova Z, Moroni-Zentgraf P, Pizzichini E (2016). The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: a Randomized Controlled Trial. Journal of Allergy and Clinical Immunology: in Practice, 4(1), 104-113.e2. Abstract.
Halpin DMG (2016). Tiotropium in asthma: What is the evidence and how does it fit in?. World Allergy Organization Journal, 9(1). Abstract.
Halpin D, Banks L, Martello A (2016). Working together to go ‘beyond the pill’: Building a virtuous network of collaborators. BMJ Innovations, 2(1), 1-3.

2015

Casale TB, Halpin DM, Engel M, Moroni-Zentgraf P, Muller A, Beeh K-M (2015). 24-HOUR EFFICACY OF TIOTROPIUM RESPIMAT (R) IN ASTHMA.  Author URL.
Halpin D, Bateman ED, Paggiaro P, Bleecker ER, Engel M, Moroni-Zentgraf P, Schmidt H, Kerstjens HAM (2015). ONCE-DAILY TIOTROPIUM RESPIMAT (R) ADD-ON TO AT LEAST ICS MAINTENANCE THERAPY REDUCES EXACERBATION RISK IN PATIENTS WITH UNCONTROLLED SYMPTOMATIC ASTHMA.  Author URL.
Saleh A, López-Campos JL, Hartl S, Pozo-Rodríguez F, Roberts CM (2015). The Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data from the European COPD Audit. PLOS ONE, 10(7), e0134004-e0134004.
Halpin DMG, Dahl R, Hallmann C, Mueller A, Tashkin D (2015). Tiotropium HandiHaler (R) and Respimat (R) in COPD: a pooled safety analysis. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 10, 239-259. Author URL.
Calverley P, Hallmann C, Metzdorf N, Grnke L, Mueller A, Halpin D (2015). Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels. Eur. Respir. J., 46(SUPPL. 59). Abstract.  Author URL.
Halpin D, Hyland M, Blake S, Seamark C, Pinnuck M, Ward D, Whalley B, Greaves C, Hawkins A, Seamark D, et al (2015). Understanding fear and anxiety in patients at the time of an exacerbation of chronic obstructive pulmonary disease: a qualitative study. JRSM Open, 6(12). Abstract.  Author URL.

2014

Sarran C, Halpin D, Levy ML, Prigmore S, Sachon P (2014). A retrospective study of the impact of a telephone alert service (Healthy Outlook) on hospital admissions for patients with chronic obstructive pulmonary disease. NPJ Prim Care Respir Med, 24 Abstract.  Author URL.
Tashkin DP, Li N, Kleerup EC, Halpin D, Celli B, Decramer M, Elashoff R (2014). Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. Respir Res, 15 Abstract.  Author URL.
Halpin D, Cooper C, Leach R (2014). Chronic Obstructive Pulmonary Disease. In  (Ed) Oxford Desk Reference: Acute Medicine, Oxford University Press. Abstract.
Chamberlain C, Williamson GR, Knight B, Daly M, Halpin DMG (2014). Investigating women’s experiences of asthma care in pregnancy: a qualitative study.  Abstract.
Tashkin DP, Li N, Kleerup E, Halpin D, Decramer M, Celli BR, Elashoff R (2014). Long-Term Trends in Acute Bronchodilator Responses over 4 Years in Patients with Mild/moderate to Very Severe COPD: Post-Hoc Analysis of Data from the Uplift Trial.  Author URL.
Halpin DMG, Paggiaro P, Bleecker E, Engel M, Moroni-Zentgraf P, Schmidt H, Kerstjens HAM (2014). ONCE-DAILY TIOTROPIUM RESPIMAT (R) ADD-ON TO AT LEAST ICS MAINTENANCE THERAPY REDUCES EXACERBATION RISK IN PATIENTS WITH UNCONTROLLED SYMPTOMATIC ASTHMA.  Author URL.
Halpin D, Bateman E, Paggiaro P, Bleecker E, Engel M, Moroni-Zentgraf P, Schmidt H, Kerstjens H (2014). Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma.  Author URL.
Halpin D, Bateman E, Paggiaro P, Bleecker E, Engel M, Moroni-Zentgraf P, Schmidt H, Kerstjens H (2014). Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma.  Author URL.
Jones RCM, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, Burden A, Halpin DMG, Winter R, Hill S, et al (2014). Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. The Lancet Respiratory Medicine, 2(4), 267-276. Abstract.
Jones RCM, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, Burden A, Halpin DMG, Winter R, Hill S, et al (2014). Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. The Lancet Respiratory Medicine
Halpin DMG, Dahl R, Hallmann C, Leimer I, Mueller A, Tashkin DP (2014). TIOTROPIUM HANDIHALER (R) AND RESPIMAT (R) IN COPD: a SAFETY ANALYSIS ON POOLED DATA.  Author URL.
Paggiaro P, Halpin DMG, Buhl R, Engel M, Zubek VB, Blahova Z, Moroni-Zentgraf P, Pizzichini E (2014). TIOTROPIUM RESPIMAT (R) ADD-ON TO INHALED CORTICOSTEROIDS IMPROVES LUNG FUNCTION IN PATIENTS WITH SYMPTOMATIC MILD ASTHMA: RESULTS FROM a PHASE III TRIAL.  Author URL.
Halpin DMG, Quint JK (2014). The WISDOM of inhaled corticosteroids in COPD. THORAX, 69(12), 1071-1072. Author URL.
Halpin DMG, Dahl R, Hallmann C, Leimer I, Kupas K, Mueller A, Tashkin DP (2014). Tiotropium Handihaler (R) and Respimat (R) in COPD: a Safety Analysis on Pooled Data.  Author URL.
Paggiaro P, Halpin DMG, Buhl R, Engel M, Zubek V, Blahova Z, Moroni-Zentgraf P, Pizzichini E (2014). Tiotropium Respimat (R) Add-On to Inhaled Corticosteroids Improves Lung Function in Patients with Symptomatic Mild Asthma: Results from a Phase III Trial.  Author URL.

2013

Tashkin DP, Li N, Halpin D, Kleerup E, Decramer M, Celli B, Elashoff R (2013). Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. Respir Med, 107(12), 1904-1911. Abstract.  Author URL.
Tashkin DP, Li N, Halpin D, Kleerup E, Decramer M, Celli BR, Elashoff R (2013). Comparison of the Annual Rates of Change in Fev1 and FVC Determined from Serial Measurements of the Pre- Vs. Post-Bronchodilator Fev1 and FVC over 4 Years in Moderate Yo Very Severe COPD: Results from the Uplift Trial.  Author URL.
Decramer M, Celli BR, Tashkin DP, Martin A, Leimer I, Metzdorf N, Halpin DM (2013). Efficacy of Tiotropium in a 4 Years Study Analyzed According to New Gold Abcd Severity Grading.  Author URL.
Halpin DMG, Holmes S, Calvert J, McInerney D (2013). FINDING THE MISSING MILLIONS: CASE FINDING FOR COPD IN PEOPLE ATTENDING OTHER LONG TERM CONDITION CLINICS IN PRIMARY CARE.  Author URL.
Chamberlain C, Williamson GR, Knight B, Daley M, Halpin DM (2013). INVESTIGATING WOMEN'S EXPERIENCES OF ASTHMA CARE IN PREGNACY: a QUALITATIVE STUDY.  Author URL.
Bernstein JA, Kerstjens HAM, Moroni-Zentgraf P, Engel M, Schmidt H, Halpin DMG (2013). Once-Daily Tiotropium is Well Tolerated as Add-On to Standard Treatment for Patients with Symptomatic Asthma Despite Receiving Inhaled Corticosteroids and Long-Acting beta(2)-Agonists.  Author URL.
Halpin DMG (2013). PREVALENCE OF SERUM EOSINOPHILIA AT TIME OF ADMISSION WITH AN EXACERBATION OF COPD.  Author URL.
Halpin DMG, Bateman ED, Tashkin DP, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, Seibold W, Moroni-Zentgraf P, et al (2013). TIOTROPIUM DECREASES THE RISK OF EXACERBATIONS IN PATIENTS WITH SYMPTOMATIC ASTHMA REGARDLESS OF BASELINE CHARACTERISTICS INCLUDING MARKERS OF ALLERGIC STATUS.  Author URL.
Halpin DMG, Bateman ED, Moroni-Zentgraf P, Engel M, Schmidt H, Kerstjens HAM (2013). TIOTROPIUM IS EFFECTIVE IN PATIENTS WITH SEVERE ASTHMA WITHOUT EVIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE.  Author URL.
Verceles AC, Lechner EJ, Halpin D, Scharf SM (2013). The association between comorbid illness, colonization status, and acute hospitalization in patients receiving prolonged mechanical ventilation. Respir Care, 58(2), 250-256. Abstract.  Author URL.
Halpin DM, Bateman ED, Moroni-Zentgraf P, Engel M, Schmidt H, Kerstjens HAM (2013). Tiotropium is Effective in Patients with Severe Asthma Without Evidence of Chronic Obstructive Pulmonary Disease.  Author URL.
Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, et al (2013). Tiotropium Respimat Inhaler and the Risk of Death in COPD. New England Journal of Medicine, 369(16), 1491-1501.

2012

Small N, Gardiner C, Barnes S, Gott M, Halpin D, Payne S, Seamark D (2012). "You get old, you get breathless, and you die": chronic obstructive pulmonary disease in Barnsley, UK. Health Place, 18(6), 1396-1403. Abstract.  Author URL.
Halpin DMG, Batten P, Chamberlain C (2012). COPD DISCHARGE BUNDLES: THE EXETER EXPERIENCE 2011-12.  Author URL.
Tashkin DP, Wang HJ, Halpin D, Kleerup EC, Connett J, Li N, Elashoff R (2012). Comparison of the variability of the annual rates of change in FEV <inf>1</inf> determined from serial measurements of the pre- versus post-bronchodilator FEV <inf>1</inf> over 5 years in mild to moderate COPD: Results of the lung health study. Respiratory Research, 13 Abstract.
Halpin D, Decramer M, Celli B, Martin A, Leimer I, Metzdorf N, Tashkin D (2012). Effectiveness of tiotropium in low-risk patients according to new GOLD severity grading.  Author URL.
Barnes S, Gardiner C, Gott M, Payne S, Chady B, Small N, Seamark D, Halpin D (2012). Enhancing patient-professional communication about end-of-life issues in life-limiting conditions: a critical review of the literature. J Pain Symptom Manage, 44(6), 866-879. Abstract.  Author URL.
Halpin DMG, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP (2012). Exacerbation frequency and course of COPD. International Journal of COPD, 7, 653-661. Abstract.
Hyland ME, Whalley B, Halpin DMG, Greaves CJ, Seamark C, Blake S, Pinnuck M, Ward D, Hawkins A, Seamark D, et al (2012). Frequency of non-asthma GP visits predicts asthma exacerbations: an observational study in general practice. Primary Care Respiratory Journal
Hyland ME, Whalley B, Halpin DMG, Greaves CJ, Seamark C, Blake S, Pinnuck M, Ward D, Hawkins AL, Seamark D, et al (2012). Frequency of non-asthma GP visits predicts asthma exacerbations: an observational study in general practice. Primary Care Respiratory Journal, 21(4), 405-411. Abstract.
Halpin D, Decramer M, Celli B, Martin A, Leimer I, Metzdorf N, Tashkin D (2012). Impact of a single chronic obstructive pulmonary disease (COPD) exacerbation on lung function decline: Analysis of UPLIFT (R).  Author URL.
Seamark D, Blake S, Seamark S, Hyland M, Greaves CJ, Pinnuck M, Ward D, Hawkins A, Halpin D (2012). Is hospitalization for COPD an opportunity for Advance Care Planning? a qualitative study. Primary Care Respiratory Journal, 21(3), 261-266. Abstract.

2011

Halpin DMG, Laing-Morton T, Spedding S, Levy ML, Coyle P, Lewis J, Newbold P, Marno P (2011). A randomised controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. Primary Care Respiratory Journal, 20(3), 324-331. Abstract.
Halpin DMG, Laing-Morton T, Spedding S, Levy ML, Coyle P, Lewis J, Newbold P, Marno P (2011). A randomised controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. Primary Care Respiratory Journal
Halpin DMG, Gray J, Edwards SJ, Morais J, Singh D (2011). Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 65(7), 764-774. Author URL.
Halpin D (2011). COPD. In  (Ed) Advanced Respiratory Critical Care, Oxford University Press. Abstract.
Halpin DMG (2011). Improving the management of COPD. BMJ, 342(7801).
Halpin D, Bakere H (2011). Pneumonia. In  (Ed) Advanced Respiratory Critical Care, Oxford University Press. Abstract.
Halpin DMG, Decramer M, Celli B, Kesten S, Leimer I, Tashkin DP (2011). Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFT (R) Trial. LUNG, 189(4), 261-268. Author URL.

2010

Marno P, Chalder M, Laing-Morton T, Levy M, Sachon P, Halpin D (2010). Can a health forecasting service offer COPD patients a novel way to manage their condition?. Journal of Health Services Research and Policy, 15(3), 150-155. Abstract.
Gardiner C, Gott M, Payne S, Small N, Barnes S, Halpin D, Ruse C, Seamark D (2010). Exploring the care needs of patients with advanced COPD: an overview of the literature. Respir Med, 104(2), 159-165. Abstract.  Author URL.
Halpin DMG (2010). Lessons from the major studies in COPD: Problems and pitfalls in translating research evidence into practice. Primary Care Respiratory Journal, 19(2), 170-179. Abstract.
Gardiner C, Barnes S, Small N, Gott M, Payne S, Seamark D, Halpin D (2010). Reconciling informed consent and 'do no harm': ethical challenges in palliative-care research and practice in chronic obstructive pulmonary disease. Palliat Med, 24(5), 469-472. Abstract.  Author URL.
Gott M, Gardiner C, Small N, Payne S, Seamark D, Halpin D, Ruse C, Barnes S (2010). The effect of the Shipman murders on clinician attitudes to prescribing opiates for dyspnoea in end-stage chronic obstructive pulmonary disease in England. Progress in Palliative Care, 18(2), 79-84. Abstract.
Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M (2010). Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT(R) trial. European Respiratory Journal, 36(1), 65-73.
Small N, Gardiner C, Barnes S, Gott M, Payne S, Seamark D, Halpin D (2010). Using a prediction of death in the next 12 months as a prompt for referral to palliative care acts to the detriment of patients with heart failure and chronic obstructive pulmonary disease. Palliat Med, 24(7), 740-741. Author URL.

2009

Hyland ME, Blake S, Greaves CJ, Pinnuck M, Seamark C, Seamark D, Ward D, Halpin DMG (2009). Authors' reply. Primary Care Respiratory Journal, 18(4).
Gott M, Gardiner C, Small N, Payne S, Seamark D, Barnes S, Halpin D, Ruse C (2009). Barriers to advance care planning in chronic obstructive pulmonary disease. Palliat Med, 23(7), 642-648. Abstract.  Author URL.
Halpin D (2009). COPD pathophysiology. In  (Ed) Oxford Desk Reference: Respiratory Medicine, Oxford University Press. Abstract.
Halpin DMG, Tashkin DP (2009). Defining disease modification in chronic obstructive pulmonary disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 6(3), 211-225. Abstract.
Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP (2009). Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. The Lancet, 374(9696), 1171-1178.
Hyland ME, Blake S, Greaves CJ, Pinnuck M, Seamark C, Seamark D, Ward D, Halpin DMG (2009). Guidelines versus practice: UK asthma nurses often recommend intermittent, symptom-driven use of inhaled corticosteroids. Prim Care Respir J, 18(2), 114-117. Abstract.  Author URL.
Gardiner C, Gott M, Small N, Payne S, Seamark D, Barnes S, Halpin D, Ruse C (2009). Living with advanced chronic obstructive pulmonary disease: patients concerns regarding death and dying. Palliat Med, 23(8), 691-697. Abstract.  Author URL.
Halpin D, Menjoge S, Viel K (2009). Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations. Prim Care Respir J, 18(2), 106-113. Abstract.  Author URL.
Halpin DMG (2009). Preventing chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 3(5), 449-452.
Bryden C, Bird W, Titley HA, Halpin DMG, Levy ML (2009). Stratification of COPD patients by previous admission for targeting of preventative care. RESPIRATORY MEDICINE, 103(4), 558-565. Author URL.

2008

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M (2008). A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 359(15), 1543-1554.
Halpin DMG (2008). ABCD of the phosphodiesterase family: Interaction and differential activity in COPD. International Journal of COPD, 3(4), 543-561. Abstract.
Price L, Kassianos G, Brown MJ, Gaw A, Kirby M, Morrell J, Schachter M, Tamargo J, Yawn B, Yawn R, et al (2008). Aliskiren - the first of a new class of antihypertensive. Drugs in Context, 4(1), 105-120. Abstract.
Chambers S, Kassianos G, Brown P, Gaw A, Kirby M, Morrell J, Schachter M, Tamargo J, Yawn B, Yawn R, et al (2008). Cervarix - Preventing cervical cancer and other diseases related to HPV. Drugs in Context, 4(1), 59-70. Abstract.
(2008). Chronic Kidney Disease National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care., Royal College of Physicians. Abstract.
Halpin DMG (2008). Community care for COPD: the good, the bad and the ugly. THORAX, 63(3), 187-189. Author URL.
Croom K, Kassianos G, Schachter M, Morrell J, Gaw A, Kirby M, Tamargo J, Yawn B, Yawn R, Barakat K, et al (2008). Coversyl Plus - Treating hypertension and improving clinical outcomes in T2D and other high risk groups. Drugs in Context, 4(1), 71-84. Abstract.
Halpin DMG, Seamark CJ, Seamark DA (2008). End-of-life care for patients with COPD in the community setting. BRITISH JOURNAL OF GENERAL PRACTICE, 58(551), 390-392. Author URL.
Croom K, Kassianos G, Gaw A, Kirby M, Morrell J, Schachler M, Tamargo J, Yawn B, Yawn R, Barakal K, et al (2008). Ezetimibe - a clinically effective and a cost-effective treatment option for dyslipidaemia. Drugs in Context, 4(1), 85-104. Abstract.
Chambers S, Kassianos G, Brown P, Gaw A, Kirby M, Morrell J, Schachter M, Tamargo J, Yawn B, Yawn R, et al (2008). Gardasil - Preventing cervical cancer and other diseases related to HPV. Drugs in Context, 4(1), 29-40. Abstract.
Crowe E, Halpin D, Stevens P, Grp GD (2008). Guidelines - Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ-BRITISH MEDICAL JOURNAL, 337(7673). Author URL.
Halpin DMG, Peterson S, Larsson TP, Calverley PMA (2008). Identifying COPD patients at increased risk of mortality: Predictive value of clinical study baseline data. Respiratory Medicine, 102(11), 1615-1624. Abstract.
Croom K, Kassianos G, Schachter M, Morrell J, Gaw A, Kirby M, Tamargo J, Yawn B, Yawn R, Barakat K, et al (2008). Inegy - Effective combination treatment to target LDL-C levels. Drugs in Context, 4(1), 41-58. Abstract.
Halpin D (2008). Mortality in COPD: Inevitable or Preventable? Insights from the Cardiovascular Arena. COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 5(3), 187-200. Author URL.
Halpin DMG (2008). Symbicort: a pharmacoeconomic review. Journal of Medical Economics, 11(2), 345-362. Abstract.
Chambers S, Schachter M, Morrell J, Kassianos G, Gaw A, Kirby M, Tamargo J, Yawn B, Yawn R, Barakat K, et al (2008). Telmisartan - an effective antihypertensive for 24-hour blood pressure control. Drugs in Context, 4(1), 1-14. Abstract.
Chambers S, Schachter M, Price D, Kassianos G, Gaw A, Kirby M, Morrell J, Tamargo J, Yawn B, Yawn R, et al (2008). Tiotropium - Advancing the treatment of COPD. Drugs in Context, 4(1), 15-28. Abstract.
Halpin DMG (2008). Uplifting times for COPD. Primary Care Respiratory Journal, 17(4), 197-198.

2007

Dodd JW, Tribe HC, Halpin DM (2007). Appropriateness of emergency oxygen therapy for COPD patients.  Author URL.
Halpin DMG, O'Reilly JF, Connellan S, Rudolf M (2007). Confidence and understanding among general practitioners and practice nurses in the UK about diagnosis and management of COPD. RESPIRATORY MEDICINE, 101(11), 2378-2385. Author URL.
Halpin DMG (2007). Management of exacerbations of chronic obstructive pulmonary disease. Minerva Pneumologica, 46(1), 5-17. Abstract.
Seamark DA, Seamark CJ, Halpin DMG (2007). Palliative care in chronic obstructive pulmonary disease: a review for clinicians. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 100(5), 225-233. Author URL.
Halpin DM (2007). Systemic effects of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 1(1), 75-84. Abstract.

2006

(2006). Anaemia Management in Chronic Kidney Disease National Clinical Guideline for Management in Adults and Children., Royal College of Physicians.
Halpin DMG (2006). Assessing the severity of COPD. Primary Care Respiratory Journal, 15(2), 78-80.
Halpin DMG (2006). Chronic obstructive pulmonary disease, inflammation and PDE4 inhibitors. BRITISH JOURNAL OF HOSPITAL MEDICINE, 67(7), 370-374. Author URL.
Halpin DMG, Miravitlles M (2006). Chronic obstructive pulmonary disease: the disease and its burden to society.  Abstract.
Halpin DMG, Rudolf M, Yıldırım N, Demir T, Turgut Y (2006). Current COPD.
Halpin DMG (2006). Diagnosing COPD. International journal of chronic obstructive pulmonary disease, 1(4), 343-344.
Halpin D (2006). Editorial. Drugs in Context, 2(6), 231-232.
Halpin DMG (2006). Health economics of chronic obstructive pulmonary disease.  Abstract.
Dyer MJ, Halpin DMG, Stein K (2006). Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review. BMC Fam Pract, 7 Abstract.  Author URL.
Bryden C, Bird W, Halpin DM, Levy ML (2006). Seasonality in chronic obstructive pulmonary disease emergency admissions to hospital, and predictability using surveillance for influenza-like illness.  Author URL.
Halpin DMG (2006). The diagnosis and management of COPD in older people. CME Journal Geriatric Medicine, 8(1), 11-17. Abstract.

2005

(2005). Beta2 agonist reversibility testing in COPD diagnosis. Drug and Therapeutics Bulletin, 43(12), 89-91.
Halpin DMG (2005). Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis. International Journal of Clinical Practice, 59(10), 1187-1194. Abstract.
Halpin DMG (2005). NICE versus nGMS: What the evidence tells us. Primary Care Respiratory Journal, 14(1), 8-10.
Greaves CJ, Hyland ME, Halpin DMG, Blake S, Seamark D (2005). Patterns of corticosteroid medication use: non-adherence can be effective in milder asthma. Prim Care Respir J, 14(2), 99-105. Abstract.  Author URL.

2004

Pearson M (2004). Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax, 59(SUPPL. 1), 1-232.
Ward DG, Halpin DMG, Seamark DA (2004). How accurate is a diagnosis of asthma in a general practice database? a review of patients' notes and questionnaire-reported symptoms. British Journal of General Practice, 54(507), 753-758. Abstract.
Seamark DA, Blake SD, Seamark CJ, Halpin DMG (2004). Living with severe chronic obstructive pulmonary disease (COPD): Perceptions of patients and their carers. An interpretative phenomenological analysis. Palliative Medicine, 18(7), 619-625. Abstract.
Halpin D (2004). NICE guidance for COPD. Thorax, 59(3), 181-182. Author URL.

2003

Halpin DMG (2003). Copd Your Questions Answered. Abstract.
Celli B, Halpin D, Hepburn R, Byrne N, Keating ET, Goldman M (2003). Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS). Respir Med, 97 Suppl A, S35-S43. Abstract.  Author URL.

2002

Greaves CJ, Eiser C, Seamark D, Halpin DMG (2002). Attack context: an important mediator of the relationship between psychological status and asthma outcomes. Thorax, 57(3), 217-221. Abstract.  Author URL.
Halpin DMG, Michael RMD (2002). Current COPD., Science Press Incorporated.
Ward JA, Akers G, Ward DG, Pinnuck M, Williams S, Trott J, Halpin DMG (2002). Feasibility and effectiveness of a pulmonary rehabilitation programme in a community hospital setting. British Journal of General Practice, 52(480), 539-542. Abstract.

2001

Sweeney KG, Edwards K, Stead J, Halpin D (2001). A comparison of professionals' and patients' understanding of asthma: Evidence of emerging dualities?. Medical Humanities, 27(1), 20-25. Abstract.
Halpin DMG (2001). COPD., Mosby Incorporated. Abstract.
Halpin D (2001). Chronic Obstructive Pulmonary Disease. In  (Ed) Respiratory Medicine, CRC Press. Abstract.
Seamark DA, Williams S, Timon S, Ward A, Ward D, Seamark C, Pinnuck M, Powell R, Halpin D (2001). Home or surgery based screening for chronic obstructive pulmonary disease (COPD)?. Primary Care Respiratory Journal, 10(2), 30-33. Abstract.
Halpin D (2001). Managing pneumonia in general practice. Practitioner, 245(1619), 108-115. Author URL.
(2001). Managing stable chronic obstructive pulmonary disease. Drug and Therapeutics Bulletin, 39(11), 81-85.

2000

Furness J, Fearby S, Clough JB, Clark CE, Coote JM, Silver DAT, Halpin DMG (2000). Asthma after childhood pneumonia. BMJ, 321(7271).
Clark CE, Coote JM, Silver DAT, Halpin DMG (2000). Asthma after childhood pneumonia - Reply. BRITISH MEDICAL JOURNAL, 321(7271), 1290-1290. Author URL.
Furness J, Fearby S, Clough JB, Clark CE, Coote JM, Silver DAT, Halpin DMG (2000). Asthma after childhood pneumonia [7] (multiple letters). British Medical Journal, 321(7271), 1289-1290.
Clark CE, Coote JM, Silver DAT, Halpin DMG (2000). Asthma after childhood pneumonia: six year follow up study. BRITISH MEDICAL JOURNAL, 320(7248), 1514-1516. Author URL.
Connolly KC, Peake MD, Halpin DMG, Golightly L, Turbitt ML (2000). Challenging current asthma treatment guidelines: Improved control of asthma symptoms with nebulised budesonide in patients with severe asthma receiving continuous oral steroids. Disease Management and Health Outcomes, 7(4), 217-225. Abstract.
Halpin DMG, Hart E, Harris T, Harbour R, Rudolf M (2000). What do general practice records tell us about the current management of COPD and the impact of the BTS COPD guidelines?. Thorax, 55(SUPPL. 3). Abstract.

1999

Halpin DMG, Williams S, Timon S, Ward AW, Ward DW, Seamark CJ, Pinnuck M, Seamark DA (1999). Home or surgery based screening for COPD?. Thorax, 54(SUPPL. 3). Abstract.

1998

Forsling ML, Montgomery H, Halpin D, Windle RJ, Treacher DF (1998). Daily patterns of secretion of neurohypophysial hormones in man: effect of age. Exp Physiol, 83(3), 409-418. Abstract.  Author URL.

1995

Bramwell EC, Halpin DMG, Duncan‐Skingle F, Hodson ME, Geddes DM (1995). Home treatment of patients with cystic fibrosis using the‘Intermate’: the first year's experience. Journal of Advanced Nursing, 22(6), 1063-1067. Abstract.

1994

Halpin DMG, Graneek BJ, Turner-Warwick M, Taylor AJN (1994). Extrinsic allergic alveolitis and asthma in a sawmill worker: Case report and review of the literature. Occupational and Environmental Medicine, 51(3), 160-164. Abstract.
Halpin DMG, Graneek BJ, Lacey J, Nieuwenhuijsen MJ, Williamson PAM, Venables KM, Taylor AJN (1994). Respiratory symptoms, immunological responses, and aeroallergen concentrations at a sawmill. Occupational and Environmental Medicine, 51(3), 165-172. Abstract.
Halpin D, Geddes D (1994). Rheumatoid arthritis and connective tissue associated obliterative bronchiolitis. In  (Ed) Diseases of the Bronchioles, Lippincott Williams & Wilkins.

1992

Halpin D (1992). Blood glucose homeostasis. In  (Ed) PHYSIOLOGY SURGICAL PRACTICE, CRC Press. Abstract.
Halpin D (1992). Growth and development. In  (Ed) PHYSIOLOGY SURGICAL PRACTICE, CRC Press. Abstract.
Halpin D (1992). Puberty, the menstrual cycle and the menopause. In  (Ed) PHYSIOLOGY SURGICAL PRACTICE, CRC Press. Abstract.
Halpin DMG, Hodson ME, Geddes DM (1992). Sex of children born to women with cystic fibrosis. The Lancet, 339(8799).
Halpin D (1992). Tests of endocrine function. In  (Ed) PHYSIOLOGY SURGICAL PRACTICE, CRC Press. Abstract.

1991

Sorrell M, Halpin DMG (1991). Art and neurology. The British Journal of Aesthetics, 31(3), 241-250.

1990

Halpin D, Collins JV (1990). Bronchoscopy. In  (Ed) Respiratory Medicine, W.B. Saunders Company. Abstract.
Halpin DMG, Burrin JM, Joplin GF (1990). Serum testosterone levels in women with Cushing's disease. Acta Endocrinologica, 122(1), 71-75. Abstract.
Halpin DM, Trend P, Symon L, Harding AE (1990). Type 1 Arnold-Chiari malformation in a 77 year old woman. J Neurol Neurosurg Psychiatry, 53(1), 88-89. Author URL.

1989

Halpin D, Wessely S (1989). VP-1 antigen in chronic postviral fatigue syndrome. Lancet, 1(8645), 1028-1029. Author URL.

1988

Halpin DMG, Charlton HM (1988). Effects of short-term injection of gonadotrophins on ovarian follicle development in hypogonadal (hpg) mice. Journal of Reproduction and Fertility, 82(1), 393-400. Abstract.
Higgins JRA, Halpin DMG, Midgley AK (1988). Tension pneumoperitoneum: a surgical emergency. British Journal of Hospital Medicine, 39(2), 160-161.

1987

Higgins JRA, Halpin DMG, Kapff PD (1987). Penetrating injury on an artificial ski slope. Injury, 18(5), 342-343.

1986

Halpin DMG, Charlton HM, Faddy MJ (1986). Effects of gonadotrophin deficiency on follicular development in hypogonadal (hpg) mice. Journal of Reproduction and Fertility, 78(1), 119-125.
Halpin DMG, Jones A, Fink G, Charlton HM (1986). Postnatal ovarian follicle development in hypogonadal (hpg) and normal mice and associated changes in the hypothalamic-pituitary ovarian axis. Journal of Reproduction and Fertility, 77(1), 287-296.

1984

Hume DA, Halpin D, Charlton H, Gordon S (1984). The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80: macrophages of endocrine organs. Proc Natl Acad Sci U S A, 81(13), 4174-4177. Abstract.  Author URL.

1983

Charlton HM, Speight A, Halpin DMG, Bramwell A, Sheward WJ, Fink G (1983). Prolactin measurements in normal and hypogonadal (hpg) mice: Developmental and experimental studies. Endocrinology, 113(2), 545-548. Abstract.
Charlton HM, Halpin DMG, Iddon C, Rosie R, Levy G, McDowell IFW, Megson A, Morris JF, Bramwell A, Speight A, et al (1983). The effects of daily administration of single and multiple injections of gonadotropin-releasing hormone on pituitary and gonadal function in the hypogonadal (hpg) mouse. Endocrinology, 113(2), 535-544. Abstract.

1982

Charlton HM, Parry D, Halpin DMG, Webb R (1982). Distribution of <sup>125</sup>I-labelled follicle-stimulating hormone and human chorionic gonadotrophin in the gonads of hypogonadal (hpg) mice. Journal of Endocrinology, 93(2), 247-252. Abstract.

1981

Charlton HM, Fink G, Halpin DMG (1981). The effects of multiple injections of gonadotrophin-releasing hormone (GnRH) in the hypogonadal mouse. Journal of Physiology, Vol.320

Refresh publications

External Engagement and Impact

Awards

  • Elected as a Fellow of European Respiratory Society in 2018 in recognition of lifetime excellence and contributions to research, education and clinical leadership in respiratory medicine.

Committee/panel activities

  • Member, Board of Directors & Science Committee, Global Obstructive Lung Disease Initiative (GOLD) since 2014
  • Vice Chair, South West Clinical Senate Council since 2015
  • Former Chair & Clinical Advisor, NICE COPD Guideline Group       
  • Former Chair, NICE Anaemia management in chronic kidney disease Guideline Group
  • Former External Examiner, MSc & Diploma in Respiratory Medicine, Imperial College, London
  • Former Chair, NICE Chronic Kidney Disease Guideline Group
  • Former Chair, Met Office COPD Health Forecasting Advisory Group
  • Former Member, NICE COPD Quality Standards Topic Expert Group
  • Former Respiratory Clinical Lead, NHS South West
  • Former Member, Department of Health COPD Commissioning Reference Group

Editorial responsibilities

  • Former Associate Editor Thorax

Invited lectures

  • Chinese College of Allergy & Asthma, 2018
  • American Thoracic Society, 2018
  • Asian Pacific Society of Respirology, Taipei, 2018
  • COPD 11, Birmingham, 2018
  • Taiwan Pulmonolgy Society, Taichung, 2018
  • Pneumo UPDATE, Budapest, 2018
  • Latin American Expert Forum, Panama, 2018
  • GOLD 2019 Meeting, Philadelphia, 2018
  • European Respiratory Society, Paris, 2018
  • Brazilian Respiratory Expert Forum, Sao Paulo, 2018
  • Korean National Respiratory Congress, Seoul
  • 2019 International Meeting on Asthma, COPD and Concomitant Disorders, Florence
  • American Thoracic Society, 2019
  • COPD Forum, Beijing, 2019
  • Pneumo UPDATE, Prague , 2019
  • Chinese Thoracic Society Satellite Meeting, Guangzhou, 2019
  • Malaysian Thoracic Society COPD Meeting, Kuala Lumpur, 2019
  • COPD Forum, Singapore , 2019
  • CUHK Advances in Medicine, Hong Kong, 2019
  • COPD Forum Changdu, 2020
  • SEPAR COVID meeting (virtual), 2020
  • American Thoracic Society (virtual), 2020
  • Taiwan Airway Forum (virtual), 2020
  • Hong Kong Thoracic Society (virtual), 2020
  • Indian COPD Webinar, 2020

Teaching

Supervision / Group

Back | Edit Profile